0001813914 false--12-31 Q2 0.0333 0.0333 0.0333 http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet http://www.caremax.com/20240630#ThirdPartyDebtCurrent http://www.caremax.com/20240630#ThirdPartyDebtCurrent http://fasb.org/us-gaap/2023#LongTermDebtNoncurrent http://fasb.org/us-gaap/2023#LongTermDebtNoncurrent 0001813914 cmax:SeriesAWarrantsAndSeriesBWarrantsMember 2023-04-01 2023-06-30 0001813914 cmax:SeriesAWarrantsAndSeriesBWarrantsMember 2024-04-01 2024-06-30 0001813914 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001813914 cmax:AdvisoryAgreementMember cmax:RelatedCmAdvisorLlcMember 2023-01-01 2023-12-31 0001813914 2024-01-01 2024-03-31 0001813914 cmax:CorporateGeneralAndAdministrativeExpensesMember us-gaap:WarrantMember cmax:AdvisoryAgreementMember 2024-04-01 2024-06-30 0001813914 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2024-06-30 0001813914 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001813914 cmax:StewardAcquisitionMember 2024-06-30 0001813914 cmax:DelayedDrawTermLoanFacilityMember 2023-06-30 0001813914 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001813914 cmax:EighthAmendmentTermLoanMember us-gaap:SubsequentEventMember 2024-07-10 2024-07-10 0001813914 us-gaap:FurnitureAndFixturesMember 2024-06-30 0001813914 cmax:MedicalCareOfNyPCAndTennesseePllcAndCareOpticalMember 2023-12-31 0001813914 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001813914 cmax:GovernmentValueMember 2023-04-01 2023-06-30 0001813914 us-gaap:CarryingReportedAmountFairValueDisclosureMember cmax:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001813914 cmax:PublicAndPrivatePlacementWarrantsMember 2024-04-01 2024-06-30 0001813914 us-gaap:RetainedEarningsMember 2023-03-31 0001813914 2023-01-01 2023-06-30 0001813914 cmax:MedicalCareOfNyPCAndTennesseePllcAndCareOpticalMember 2024-06-30 0001813914 us-gaap:OtherCurrentLiabilitiesMember 2023-12-31 0001813914 cmax:TwoThousandTwentyOneLongTermIncentivePlanMember 2023-04-01 2023-06-30 0001813914 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001813914 2023-01-01 2023-12-31 0001813914 2022-05-31 0001813914 cmax:StewardAcquisitionMember 2023-12-31 0001813914 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001813914 us-gaap:NoncompeteAgreementsMember 2024-01-01 2024-06-30 0001813914 us-gaap:FairValueInputsLevel1Member cmax:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001813914 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001813914 us-gaap:TrademarksMember 2024-06-30 0001813914 2024-03-15 0001813914 cmax:MedicaidMember 2023-01-01 2023-06-30 0001813914 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember cmax:PayorEMember 2023-04-01 2023-06-30 0001813914 us-gaap:ContractBasedIntangibleAssetsMember 2023-12-31 0001813914 us-gaap:CarryingReportedAmountFairValueDisclosureMember cmax:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001813914 us-gaap:WarrantMember cmax:AdvisoryAgreementMember 2024-06-30 0001813914 us-gaap:OtherCurrentLiabilitiesMember 2024-06-30 0001813914 srt:ScenarioForecastMember 2026-07-01 2026-09-30 0001813914 us-gaap:ProductAndServiceOtherMember 2023-04-01 2023-06-30 0001813914 cmax:CorporateGeneralAndAdministrativeExpensesMember cmax:StewardAcquisitionMember 2024-01-01 2024-06-30 0001813914 us-gaap:CreditConcentrationRiskMember cmax:PayorAMember us-gaap:AccountsReceivableMember 2023-01-01 2023-12-31 0001813914 us-gaap:ConstructionInProgressMember 2024-06-30 0001813914 srt:MaximumMember 2024-04-01 2024-06-30 0001813914 cmax:ContingentConsiderationMember 2023-04-01 2023-06-30 0001813914 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001813914 us-gaap:TrademarksMember 2023-12-31 0001813914 cmax:CreditAgreementMember 2024-06-30 0001813914 cmax:RelatedCmAdvisorLlcMember cmax:AdvisoryAgreementMember 2024-01-01 2024-06-30 0001813914 cmax:PublicAndPrivatePlacementWarrantsMember 2024-01-01 2024-06-30 0001813914 cmax:BeginningOnThirdAnniversaryMember 2023-03-08 2023-03-08 0001813914 cmax:OtherLongTermDebtMember 2024-06-30 0001813914 us-gaap:PerformanceSharesMember 2024-04-01 2024-06-30 0001813914 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2023-12-31 0001813914 2024-03-15 2024-03-15 0001813914 us-gaap:CommonStockMember 2024-06-30 0001813914 cmax:PayorDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001813914 us-gaap:ContractBasedIntangibleAssetsMember 2024-01-01 2024-06-30 0001813914 cmax:AdvisoryAgreementMember cmax:RelatedCmAdvisorLlcMember 2021-07-13 0001813914 cmax:PayorBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001813914 2024-01-31 2024-01-31 0001813914 cmax:PayorAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001813914 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001813914 cmax:PayorBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001813914 cmax:PayorCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001813914 us-gaap:FairValueInputsLevel1Member cmax:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001813914 us-gaap:RevolvingCreditFacilityMember 2023-03-08 0001813914 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001813914 us-gaap:NoncompeteAgreementsMember 2024-06-30 0001813914 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-06-30 0001813914 cmax:PayorCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001813914 cmax:CorporateGeneralAndAdministrativeExpensesMember cmax:StewardAcquisitionMember 2023-04-01 2023-06-30 0001813914 cmax:CorporateGeneralAndAdministrativeExpensesMember cmax:StewardAcquisitionMember 2023-01-01 2023-06-30 0001813914 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001813914 srt:MinimumMember 2024-01-01 2024-06-30 0001813914 cmax:DelayedDrawTermLoanFacilityMember 2022-11-01 2022-11-30 0001813914 cmax:TwoThousandTwentyOneLongTermIncentivePlanMember 2024-01-01 2024-06-30 0001813914 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2023-12-31 0001813914 cmax:EighthAmendmentTermLoanMember cmax:IncrementalDelayedDrawTermLoanFacilityMember us-gaap:SubsequentEventMember 2024-07-10 0001813914 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001813914 us-gaap:CommonStockMember 2024-03-31 0001813914 us-gaap:CommonStockMember 2023-06-30 0001813914 cmax:TwoThousandTwentyOneLongTermIncentivePlanMember 2023-01-01 2023-06-30 0001813914 2023-06-30 0001813914 cmax:AnthemMember us-gaap:CommercialPaperMember 2022-10-31 0001813914 cmax:TwoThousandTwentyOneLongTermIncentivePlanMember 2024-06-30 0001813914 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001813914 cmax:ProviderNetworkMember 2024-06-30 0001813914 cmax:ContingentConsiderationMember 2024-01-01 2024-06-30 0001813914 cmax:MedicaidMember 2024-04-01 2024-06-30 0001813914 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001813914 us-gaap:RetainedEarningsMember 2023-12-31 0001813914 2024-06-30 0001813914 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember cmax:PayorFMember 2023-04-01 2023-06-30 0001813914 us-gaap:OtherAssetsMember 2023-12-31 0001813914 cmax:ContingentConsiderationMember 2024-04-01 2024-06-30 0001813914 us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001813914 cmax:MedicareMember 2023-01-01 2023-06-30 0001813914 us-gaap:PerformanceSharesMember 2023-01-01 2023-06-30 0001813914 cmax:SeriesAWarrantsAndSeriesBWarrantsMember 2024-01-01 2024-06-30 0001813914 2022-11-30 0001813914 us-gaap:ProductAndServiceOtherMember 2024-04-01 2024-06-30 0001813914 us-gaap:RetainedEarningsMember 2024-06-30 0001813914 cmax:TwoThousandTwentyOneLongTermIncentivePlanMember us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001813914 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001813914 us-gaap:CarryingReportedAmountFairValueDisclosureMember cmax:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001813914 2024-04-01 2024-06-30 0001813914 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-06-30 0001813914 us-gaap:ConstructionInProgressMember 2023-12-31 0001813914 cmax:MedicalCareOfNyPCAndTennesseePllcAndCareOpticalMember 2023-04-01 2023-06-30 0001813914 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001813914 cmax:BeginningOnSecondAnniversaryMember 2023-03-08 2023-03-08 0001813914 cmax:ContingentConsiderationMember 2023-01-01 2023-06-30 0001813914 cmax:PayorCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001813914 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001813914 us-gaap:WarrantMember cmax:AdvisoryAgreementMember 2023-12-31 0001813914 us-gaap:OtherAssetsMember 2024-06-30 0001813914 cmax:EighthAmendmentTermLoanMember us-gaap:SubsequentEventMember 2024-07-10 0001813914 cmax:CorporateGeneralAndAdministrativeExpensesMember cmax:StewardAcquisitionMember 2024-04-01 2024-06-30 0001813914 us-gaap:FairValueInputsLevel3Member cmax:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001813914 us-gaap:CommonClassBMember 2024-08-06 0001813914 cmax:MedicalCareOfNyPCAndTennesseePllcAndCareOpticalMember 2023-01-01 2023-06-30 0001813914 us-gaap:ContractBasedIntangibleAssetsMember 2024-06-30 0001813914 cmax:CareMaxMedicalGroupLimitedLiabilityCompanyMember cmax:BusinessCombinationAgreementMember 2021-06-08 0001813914 cmax:ProviderNetworkMember 2024-01-01 2024-06-30 0001813914 2024-03-31 0001813914 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001813914 2022-12-31 0001813914 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001813914 cmax:FinanceLeaseObligationsMember 2023-12-31 0001813914 cmax:TermLoanFacilityMember 2022-11-30 0001813914 cmax:PayorAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001813914 cmax:DelayedDrawTermLoanFacilityMember 2024-06-30 0001813914 us-gaap:VehiclesMember 2023-12-31 0001813914 cmax:MedicalCareOfNyPCAndTennesseePllcAndCareOpticalMember 2024-04-01 2024-06-30 0001813914 us-gaap:CommonClassAMember 2023-12-31 0001813914 cmax:SeriesAWarrantsAndSeriesBWarrantsMember 2023-01-01 2023-06-30 0001813914 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember cmax:FloatingRateDebtMember 2023-12-31 0001813914 cmax:MedicareMember 2024-01-01 2024-06-30 0001813914 us-gaap:TrademarksMember 2024-01-01 2024-06-30 0001813914 us-gaap:RevenueFromContractWithCustomerMember cmax:PayorEMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001813914 us-gaap:WarrantMember cmax:CorporateGeneralAndAdministrativeExpensesMember cmax:AdvisoryAgreementMember 2024-01-01 2024-06-30 0001813914 cmax:OtherMember 2024-01-01 2024-06-30 0001813914 2023-03-08 2023-03-08 0001813914 cmax:WarrantsMember 2024-01-01 2024-06-30 0001813914 us-gaap:RetainedEarningsMember 2023-06-30 0001813914 cmax:MedicaidMember 2024-01-01 2024-06-30 0001813914 2024-01-01 2024-06-30 0001813914 2023-10-01 2023-10-31 0001813914 cmax:DelayedDrawTermLoanBFacilityMember 2023-03-08 0001813914 us-gaap:RetainedEarningsMember 2022-12-31 0001813914 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001813914 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001813914 cmax:FinanceLeaseObligationsMember 2024-06-30 0001813914 us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-06-30 0001813914 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001813914 cmax:MedicareMember 2024-04-01 2024-06-30 0001813914 cmax:OtherMember 2023-12-31 0001813914 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001813914 us-gaap:CommonStockMember 2023-12-31 0001813914 us-gaap:PerformanceSharesMember 2024-01-01 2024-06-30 0001813914 us-gaap:PerformanceSharesMember 2023-04-01 2023-06-30 0001813914 us-gaap:NoncompeteAgreementsMember 2023-12-31 0001813914 cmax:TwoThousandTwentyOneLongTermIncentivePlanMember 2024-04-01 2024-06-30 0001813914 us-gaap:VehiclesMember 2024-06-30 0001813914 cmax:ProviderNetworkMember 2023-12-31 0001813914 us-gaap:WarrantMember cmax:CorporateGeneralAndAdministrativeExpensesMember cmax:AdvisoryAgreementMember 2023-01-01 2023-06-30 0001813914 2023-01-01 2023-03-31 0001813914 cmax:PayorCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001813914 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001813914 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001813914 2023-04-01 2023-06-30 0001813914 srt:MinimumMember cmax:CreditAgreementMember 2024-06-30 0001813914 srt:MaximumMember 2024-01-01 2024-06-30 0001813914 cmax:BeginningOnDecemberTenTwoThousandTwentyTwoMember 2023-03-08 2023-03-08 0001813914 us-gaap:SoftwareDevelopmentMember 2024-06-30 0001813914 cmax:PayorBMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001813914 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001813914 2022-11-01 2022-11-30 0001813914 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001813914 cmax:AssetsUnderFinanceLeasesMember 2023-12-31 0001813914 cmax:GovernmentValueMember 2024-04-01 2024-06-30 0001813914 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001813914 2023-12-31 0001813914 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001813914 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember cmax:PayorEMember 2024-04-01 2024-06-30 0001813914 cmax:PayorAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001813914 2022-01-01 2022-06-30 0001813914 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001813914 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember cmax:PayorEMember 2023-01-01 2023-06-30 0001813914 us-gaap:CommonStockMember 2023-03-31 0001813914 cmax:GovernmentValueMember 2023-01-01 2023-06-30 0001813914 cmax:PayorDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001813914 cmax:IMCMedicalGroupHoldingsMember cmax:BusinessCombinationAgreementMember 2021-06-08 0001813914 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2024-06-30 0001813914 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001813914 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001813914 cmax:DelayedDrawTermLoanFacilityMember 2022-05-31 0001813914 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember cmax:PayorFMember 2024-01-01 2024-06-30 0001813914 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001813914 cmax:PayorDMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001813914 cmax:PublicAndPrivatePlacementWarrantsMember 2023-01-01 2023-06-30 0001813914 us-gaap:RetainedEarningsMember 2024-03-31 0001813914 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001813914 cmax:CreditAgreementMember 2023-12-31 0001813914 cmax:InitialTermLoansMember cmax:TermSOFRMember 2024-06-30 0001813914 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember cmax:FloatingRateDebtMember 2023-12-31 0001813914 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001813914 cmax:InitialTermLoansMember 2022-05-31 0001813914 cmax:MedicaidMember 2023-04-01 2023-06-30 0001813914 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember cmax:FloatingRateDebtMember 2024-06-30 0001813914 us-gaap:CommonStockMember 2022-12-31 0001813914 cmax:PublicAndPrivatePlacementWarrantsMember 2023-04-01 2023-06-30 0001813914 cmax:GovernmentValueMember 2024-01-01 2024-06-30 0001813914 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember cmax:FloatingRateDebtMember 2024-06-30 0001813914 2022-05-01 2022-05-31 0001813914 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember cmax:FixedRateDebtMember 2024-06-30 0001813914 cmax:DelayedDrawTermLoanFacilityMember 2023-03-08 2023-03-08 0001813914 us-gaap:CommonClassAMember 2024-08-06 0001813914 cmax:TwoThousandTwentyOneLongTermIncentivePlanMember 2023-06-30 0001813914 us-gaap:CreditConcentrationRiskMember cmax:PayorBMember us-gaap:AccountsReceivableMember 2023-01-01 2023-12-31 0001813914 cmax:MedicalCareOfNyPCAndTennesseePllcAndCareOpticalMember 2024-01-01 2024-06-30 0001813914 cmax:OtherMember 2024-06-30 0001813914 2023-03-31 0001813914 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember cmax:FixedRateDebtMember 2023-12-31 0001813914 cmax:OtherLongTermDebtMember 2023-12-31 0001813914 cmax:AnthemMember us-gaap:CommercialPaperMember 2022-10-01 2022-10-31 0001813914 us-gaap:CarryingReportedAmountFairValueDisclosureMember cmax:FixedRateDebtMember us-gaap:FairValueMeasurementsNonrecurringMember 2024-06-30 0001813914 cmax:PayorAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001813914 cmax:TwoThousandTwentyOneLongTermIncentivePlanMember us-gaap:CommonClassAMember 2024-06-30 0001813914 cmax:EighthAmendmentTermLoanMember us-gaap:SubsequentEventMember cmax:TermSOFRMember 2024-07-10 0001813914 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001813914 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001813914 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001813914 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember cmax:PayorFMember 2023-01-01 2023-12-31 0001813914 cmax:DelayedDrawTermLoanFacilityMember 2023-03-08 0001813914 cmax:MedicareMember 2023-04-01 2023-06-30 0001813914 us-gaap:WarrantMember cmax:CorporateGeneralAndAdministrativeExpensesMember cmax:AdvisoryAgreementMember 2023-04-01 2023-06-30 0001813914 us-gaap:CommonClassAMember 2024-06-30 0001813914 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001813914 cmax:AnthemMember us-gaap:CommercialPaperMember 2024-06-30 0001813914 us-gaap:FairValueInputsLevel3Member cmax:FixedRateDebtMember us-gaap:FairValueMeasurementsNonrecurringMember 2023-12-31 iso4217:USD xbrli:shares xbrli:pure xbrli:shares cmax:State cmax:Center iso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-39391

CareMax, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware | 85-0992224
( State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)
1000 NW 57th Court, Suite 400 Miami, FL | 33126
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (786) 360-4768

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Class A common stock, par value $0.0001 per share |  | CMAX |  | The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for 1/30th of one share of Class A common stock |  | CMAXW |  | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer |  | ☐ |  | Accelerated filer |  | ☒
Non-accelerated filer |  | ☐ |  | Smaller reporting company |  | ☒
|  |  |  | Emerging growth company |  | ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by check mark whether t he registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐

As of August 6, 2024, the registrant had 3,814,971 shares of Class A common stock, $0.0001 par value per share, and no shares of Class B common stock, $0.0001 par value per share issued and outstanding.

CareMax, Inc.

Quarterly Report on Form 10-Q

For the Quarter Ended June 30, 2024

Table of Contents

PART I. FINANCIAL INFORMATION |
| Item 1 | Condensed Consolidated Balance Sheets | 1
|  | Condensed Consolidated Statements of Operations | 2
|  | Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity | 3
|  | Condensed Consolidated Statements of Cash Flows | 4
|  | Notes to Condensed Consolidated Financial Statements | 6
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 24
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 44
| Item 4. | Controls and Procedures | 45
PART II. OTHER INFORMATION | 47
| Item 1. | Legal Proceedings | 47
| Item 1A. | Risk Factors | 47
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 47
| Item 3. | Defaults Upon Senior Securities | 47
| Item 4. | Mine Safety Disclosures | 47
| Item 5. | Other Information | 47
| Item 6. | Exhibits | 48

PART I – FINAN CIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CAREMAX, INC.

CONDENSED CONSOLIDA TED BALANCE SHEETS

(Unaudited)

(in thousands, except share and per share data)

|  | June 30, 2024 |  |  | December 31, 2023 |
ASSETS |  |  |  |  |  |
Current Assets |  |  |  |  |  |
Cash and cash equivalents |  | $ | 16,430 |  |  | $ | 65,528 |
Accounts receivable, net |  |  | 97,488 |  |  |  | 114,754 |
Other current assets |  |  | 9,547 |  |  |  | 3,066 |
Total Current Assets |  |  | 123,466 |  |  |  | 183,348 |
Property and equipment, net |  |  | 21,419 |  |  |  | 47,918 |
Operating lease right-of-use assets |  |  | 48,424 |  |  |  | 109,215 |
Goodwill, net |  |  | 156,841 |  |  |  | 156,841 |
Intangible assets, net |  |  | 42,163 |  |  |  | 101,243 |
Other assets |  |  | 61,730 |  |  |  | 24,737 |
Total Assets |  | $ | 454,043 |  |  | $ | 623,301 |
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |
Accounts payable |  | $ | 8,453 |  |  | $ | 6,275 |
Accrued expenses |  |  | 13,257 |  |  |  | 16,224 |
Risk settlement liabilities |  |  | 59,204 |  |  |  | 42,602 |
Related party liabilities |  |  | 1,772 |  |  |  | 190 |
Current portion of third-party debt, net |  |  | 403,321 |  |  |  | 364,380 |
Current portion of operating lease liabilities |  |  | 43,646 |  |  |  | 8,975 |
Other current liabilities |  |  | 17 |  |  |  | 165 |
Total Current Liabilities |  |  | 529,671 |  |  |  | 438,812 |
Derivative liabilities |  |  | 48 |  |  |  | 22 |
Long-term debt, net |  |  | 1,785 |  |  |  | 21,443 |
Long-term operating lease liabilities |  |  | 64,455 |  |  |  | 97,136 |
Other liabilities |  |  | 5,844 |  |  |  | 4,443 |
Total Liabilities |  |  | 601,803 |  |  |  | 561,856 |
COMMITMENTS AND CONTINGENCIES (NOTE 14) |  |  |  |  |  |
STOCKHOLDERS’ (DEFICIT) EQUITY |  |  |  |  |  |
Preferred stock (1,000,000 shares authorized; one share issued and outstanding as of June 30, 2024 and December 31, 2023) |  |  | — |  |  |  | — |
Class A common stock ($0.0001 par value; 8,333,333 shares authorized; 3,814,871 and 3,744,732 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively) |  |  | 11 |  |  |  | 11 |
Additional paid-in-capital |  |  | 787,132 |  |  |  | 782,371 |
Accumulated deficit |  |  | (934,902 | ) |  |  | (720,938 | )
Total Stockholders’ (Deficit) Equity |  |  | (147,759 | ) |  |  | 61,444 |
Total Liabilities and Stockholders’ (Deficit) Equity |  | $ | 454,043 |  |  | $ | 623,301 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(1)

CAREMAX, INC.

CONDENSED CONSOLIDATED ST ATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except share and per share data)

| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Revenue |  |  |  |  |  |  |  |  |  |  |
Medicare risk-based revenue | $ | 154,857 |  |  | $ | 155,486 |  |  | $ | 323,359 |  |  | $ | 277,079 |
Medicaid risk-based revenue |  | 22,865 |  |  |  | 30,054 |  |  |  | 60,518 |  |  |  | 55,680 |
Government value-based care revenue |  | 14,690 |  |  |  | 22,206 |  |  |  | 33,505 |  |  |  | 32,216 |
Other revenue |  | 6,215 |  |  |  | 16,694 |  |  |  | 13,491 |  |  |  | 32,449 |
Total revenue |  | 198,627 |  |  |  | 224,440 |  |  |  | 430,872 |  |  |  | 397,424 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |
External provider costs |  | 153,115 |  |  |  | 156,995 |  |  |  | 334,056 |  |  |  | 267,668 |
Cost of care |  | 42,593 |  |  |  | 40,192 |  |  |  | 85,726 |  |  |  | 78,819 |
Sales and marketing |  | 1,378 |  |  |  | 3,327 |  |  |  | 4,441 |  |  |  | 7,092 |
Corporate, general and administrative |  | 14,780 |  |  |  | 20,849 |  |  |  | 34,888 |  |  |  | 44,813 |
Depreciation and amortization |  | 6,512 |  |  |  | 6,828 |  |  |  | 13,218 |  |  |  | 13,404 |
Impairment of long-lived assets (note 1) |  | 132,990 |  |  |  | — |  |  |  | 132,990 |  |  |  | — |
Goodwill impairment |  | — |  |  |  | — |  |  |  | — |  |  |  | 98,000 |
Total operating expenses |  | 351,368 |  |  |  | 228,191 |  |  |  | 605,318 |  |  |  | 509,797 |
Operating loss |  | (152,741 | ) |  |  | (3,750 | ) |  |  | (174,446 | ) |  |  | (112,373 | )
Nonoperating (expenses) income |  |  |  |  |  |  |  |  |  |  |
Interest expense |  | (20,376 | ) |  |  | (13,197 | ) |  |  | (40,131 | ) |  |  | (23,908 | )
Change in fair value of derivative liabilities |  | 2,355 |  |  |  | 434 |  |  |  | (26 | ) |  |  | 1,540 |
(Loss) gain on remeasurement of contingent earnout liabilities |  | — |  |  |  | (16,220 | ) |  |  | — |  |  |  | 19,916 |
Other income, net |  | 382 |  |  |  | 534 |  |  |  | 992 |  |  |  | 721 |
Total nonoperating expenses |  | (17,639 | ) |  |  | (28,449 | ) |  |  | (39,165 | ) |  |  | (1,730 | )
Loss before income tax |  | (170,381 | ) |  |  | (32,199 | ) |  |  | (213,612 | ) |  |  | (114,103 | )
Income tax expense |  | (177 | ) |  |  | (177 | ) |  |  | (354 | ) |  |  | (355 | )
Net loss | $ | (170,558 | ) |  | $ | (32,376 | ) |  | $ | (213,966 | ) |  | $ | (114,458 | )
Weighted-average basic shares outstanding 1 |  | 3,807,551 |  |  |  | 3,722,377 |  |  |  | 3,793,076 |  |  |  | 3,717,040 |
Weighted-average diluted shares outstanding 1 |  | 3,807,551 |  |  |  | 3,722,377 |  |  |  | 3,793,076 |  |  |  | 3,717,040 |
Net loss per share |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (44.79 | ) |  | $ | (8.70 | ) |  | $ | (56.41 | ) |  | $ | (30.79 | )
Diluted | $ | (44.79 | ) |  | $ | (8.70 | ) |  | $ | (56.41 | ) |  | $ | (30.79 | )
1 Share amounts have been restated to reflect the 1-for-30 reverse stock split that the Company completed on January 31, 2024. |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(2)

CAREMAX, INC.

CONDENSED CONSOLIDATED STAT EMENTS OF CHANGES IN STOCKHOLDERS’ (DEFICIT) EQUITY

(Unaudited)

(in thousands, except share data)

|  | Three Months Ended June 30, 2024 and 2023 |
|  | Class A Common Stock |  |  | Preferred |  |  | Additional |  |  | Accumulated |  |  | Total Stockholders’ |
|  | Shares |  |  | Amount |  |  | Stock |  |  | Paid-in-capital |  |  | Deficit |  |  | (Deficit) Equity |
BALANCE - MARCH 31, 2024 |  |  | 3,802,883 |  |  | $ | 11 |  |  | $ | — |  |  | $ | 784,736 |  |  | $ | (764,345 | ) |  | $ | 20,403 |
Stock-based compensation expense |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,396 |  |  |  | — |  |  |  | 2,396 |
Issuance of shares upon vesting of stock-based compensation awards |  |  | 11,988 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (170,558 | ) |  |  | (170,558 | )
BALANCE - JUNE 30, 2024 |  |  | 3,814,871 |  |  | $ | 11 |  |  | $ | — |  |  | $ | 787,132 |  |  | $ | (934,902 | ) |  | $ | (147,759 | )
BALANCE - MARCH 31, 2023 |  |  | 3,712,027 |  |  | $ | 11 |  |  | $ | — |  |  | $ | 659,424 |  |  | $ | (119,672 | ) |  | $ | 539,763 |
Stock-based compensation expense |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,464 |  |  |  | — |  |  |  | 2,464 |
Issuance of shares upon vesting of stock-based compensation awards |  |  | 23,715 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Reclassification of contingent consideration previously liability classified |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 114,645 |  |  |  | — |  |  |  | 114,645 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (32,376 | ) |  |  | (32,376 | )
BALANCE - JUNE 30, 2023 |  |  | 3,735,741 |  |  | $ | 11 |  |  | $ | — |  |  | $ | 776,533 |  |  | $ | (152,048 | ) |  | $ | 624,496 |

|  | Six Months Ended June 30, 2024 and 2023 |
|  | Class A Common Stock |  |  | Preferred |  |  | Additional |  |  | Accumulated |  |  | Total Stockholders’ |
|  | Shares |  |  | Amount |  |  | Stock |  |  | Paid-in-capital |  |  | Deficit |  |  | (Deficit) Equity |
BALANCE - DECEMBER 31, 2023 |  |  | 3,744,732 |  |  | $ | 11 |  |  | $ | — |  |  | $ | 782,371 |  |  | $ | (720,938 | ) |  | $ | 61,444 |
Stock-based compensation expense |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,761 |  |  |  | — |  |  |  | 4,761 |
Issuance of shares upon vesting of stock-based compensation awards |  |  | 70,139 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (213,966 | ) |  |  | (213,966 | )
BALANCE - JUNE 30, 2024 |  |  | 3,814,871 |  |  | $ | 11 |  |  | $ | — |  |  | $ | 787,132 |  |  | $ | (934,902 | ) |  | $ | (147,759 | )
BALANCE - DECEMBER 31, 2022 |  |  | 3,711,086 |  |  | $ | 11 |  |  | $ | — |  |  | $ | 657,126 |  |  | $ | (37,590 | ) |  | $ | 619,547 |
Stock-based compensation expense |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,762 |  |  |  | — |  |  |  | 4,762 |
Issuance of shares upon vesting of stock-based compensation awards |  |  | 24,655 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Reclassification of contingent consideration previously liability classified |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 114,645 |  |  |  | — |  |  |  | 114,645 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (114,458 | ) |  |  | (114,458 | )
BALANCE - JUNE 30, 2023 |  |  | 3,735,741 |  |  | $ | 11 |  |  | $ | — |  |  | $ | 776,533 |  |  | $ | (152,048 | ) |  | $ | 624,496 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(3)

CAREMAX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

|  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |
CASH FLOWS FROM OPERATING ACTIVITIES |  |  |  |  |  |
Net loss |  | $ | (213,966 | ) |  | $ | (114,458 | )
Adjustments to reconcile net loss to cash and cash equivalents: |  |  |  |  |  |
Depreciation and amortization expense |  |  | 13,218 |  |  |  | 13,404 |
Amortization of debt issuance costs and discounts |  |  | 1,821 |  |  |  | 4,086 |
Impairment of long-lived assets |  |  | 132,990 |  |  |  | — |
Stock-based compensation expense |  |  | 4,761 |  |  |  | 4,762 |
Deferred income taxes |  |  | 354 |  |  |  | 355 |
Change in fair value of derivative liabilities |  |  | 26 |  |  |  | (1,540 | )
Gain on remeasurement of contingent earnout liabilities |  |  | — |  |  |  | (19,916 | )
Payment-in-kind interest expense |  |  | 21,955 |  |  |  | 5,500 |
Non-cash finance lease expense |  |  | 293 |  |  |  | — |
Provision for credit losses |  |  | (307 | ) |  |  | 57 |
Goodwill impairment |  |  | — |  |  |  | 98,000 |
Amortization of right-of-use assets |  |  | 5,325 |  |  |  | 5,842 |
Other non-cash, net |  |  | 33 |  |  |  | 1,213 |
Changes in operating assets and liabilities: |  |  |  |  |  |
Accounts receivable |  |  | 17,573 |  |  |  | (1,255 | )
Other current assets |  |  | (6,481 | ) |  |  | 452 |
Risk settlement liabilities |  |  | 16,602 |  |  |  | 1,968 |
Other assets |  |  | (41,749 | ) |  |  | (41,807 | )
Operating lease liabilities |  |  | (1,577 | ) |  |  | (4,959 | )
Accounts payable |  |  | 1,502 |  |  |  | (128 | )
Accrued expenses |  |  | (2,967 | ) |  |  | (4,219 | )
Related party liabilities |  |  | 1,582 |  |  |  | (1,134 | )
Other liabilities |  |  | 898 |  |  |  | 10,515 |
Net cash used in operating activities |  |  | (48,114 | ) |  |  | (43,263 | )
CASH FLOWS FROM INVESTING ACTIVITIES |  |  |  |  |  |
Purchases of property and equipment |  |  | (794 | ) |  |  | (5,234 | )
Net cash used in investing activities |  |  | (794 | ) |  |  | (5,234 | )
CASH FLOWS FROM FINANCING ACTIVITIES |  |  |  |  |  |
Proceeds from borrowings, net |  |  | — |  |  |  | 62,000 |
Principal payments of debt |  |  | (189 | ) |  |  | (125 | )
Payments of debt issuance costs |  |  | — |  |  |  | (398 | )
Net cash (used in) provided by financing activities |  |  | (189 | ) |  |  | 61,477 |
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS |  |  | (49,097 | ) |  |  | 12,980 |
Cash and cash equivalents - beginning of period |  |  | 65,528 |  |  |  | 41,626 |
CASH AND CASH EQUIVALENTS - END OF PERIOD |  | $ | 16,430 |  |  | $ | 54,605 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(4)

CAREMAX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)

(Unaudited)

(in thousands)

|  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES: |  |  |  |  |  |
Additions to property and equipment funded through accounts payable |  | $ | 676 |  |  | $ | 1,118 |
Reclassification of contingent consideration previously liability classified |  |  | — |  |  |  | 114,645 |
Financed property and equipment purchases |  |  | 168 |  |  |  | — |
Change in right-of-use assets and lease liabilities due to lease remeasurements |  |  | 2,560 |  |  |  | 2,151 |
Right-of-use assets obtained in exchange for operating lease obligations |  |  | 4,388 |  |  |  | — |
SUPPLEMENTAL CASH FLOW INFORMATION: |  |  |  |  |  |
Cash paid for interest |  |  | 8,964 |  |  |  | 14,609 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(5)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

Note 1. DESCRIPTION of business and going concern

CareMax, Inc. (“CareMax” or the “Company”), formerly Deerfield Healthcare Technology Acquisitions Corp. (“DFHT”), is a Delaware corporation, which announced its initial public offering in July 2020 (the “IPO”) as a publicly traded special purpose acquisition company for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination involving one or more businesses. CareMax provides high-quality, value-based care and chronic disease management through physicians and health care professionals committed to the overall health and wellness continuum of care for its patients. As of June 30, 2024, the Company operated 50 centers and managed affiliated providers across 10 states that offer a comprehensive suite of healthcare and social services, and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.

The Business Combination and Acquisitions

On December 18, 2020, DFHT entered into a Business Combination Agreement (the “Business Combination Agreement”) with CareMax Medical Group, L.L.C., a Florida limited liability company (“CMG”), and entities listed in the Business Combination Agreement, IMC Medical Group Holdings, LLC, a Delaware limited liability company (“IMC”), IMC Holdings, LP, a Delaware limited partnership, and Deerfield Partners, L.P. The Business Combination (as defined below) closed on June 8, 2021 (the “Closing Date”), whereby DFHT acquired 100% of the equity interests in CMG and 100% of the equity interests in IMC, with CMG and IMC becoming wholly owned subsidiaries of DFHT. Immediately upon completion (the “Closing”) of the transactions contemplated by the Business Combination Agreement and the related financing transactions (the “Business Combination”), the name of the combined company was changed to CareMax, Inc.

Unless the context otherwise requires, “the Company,” “we,” “us,” and “our” refer, for periods prior to the completion of the Business Combination, to CMG and its subsidiaries, and, for periods upon or after the completion of the Business Combination, to CareMax, Inc. and its subsidiaries.

Subsequent to consummation of the Business Combination, primarily during the second half of 2021, the Company acquired Senior Medical Associates, LLC, Stallion Medical Management, LLC, Unlimited Medical Services of Florida, LLC, Advantis Physician Alliance, LLC, Business Intelligence & Analytics LLC, and three additional businesses.

In November 2022, the Company acquired the Medicare value-based care business of Steward Health Care System (“Steward Value Based Care”, and such transaction the “Steward Acquisition”). On May 6, 2024, Steward Health Care System LLC (“Steward Health Care System”) and certain of its affiliates commenced an in-court restructuring process through the filing of voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas. As previously disclosed, the Company entered into or acquired certain contracts with affiliates of Steward Health Care System in connection with the Steward Acquisition. In June 2024, as part of these bankruptcy proceedings, Steward Health Care System moved to reject certain of such executory contracts. Refer to Note 5, Goodwill and Other Intangible Assets, for further information.

Going Concern

The Company’s condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has generated recurring losses and negative cash flows from operations since completion of the Business Combination, and believes that, absent the Company successfully taking certain measures to reduce operating expenses and/or divest certain assets or businesses, as set forth below, the Company will continue to incur net losses and negative cash flows for the foreseeable future. The Company obtained a limited waiver of certain breaches of financial and administrative covenants under the Credit Agreement (as defined below) through August 15, 2024, subject to an earlier termination of the waiver upon the occurrence of certain specified events, as further explained in Note 7, Debt and Related Party Debt. Further, as of June 30, 2024, the Company was in breach of certain financial and administrative covenants (such as the failure to pay rent when it came due) and were in default under certain of its lease agreements, as further explained in Note 12, Leases. Although the Company had $16.4 million in cash and cash equivalents and $97.5 million of accounts receivable, net, at June 30, 2024, absent the Company successfully implementing management’s plans as set forth below, the Company believes it will not be able to comply with the minimum liquidity requirement and maximum leverage ratio covenants contained in its Credit Agreement once the current limited waiver expires, nor will it be able to comply with certain financial

(6)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

covenants under certain of the Company’s leases. The Company has appointed a Chief Restructuring Officer and engaged external consultants to provide it with restructuring and transactional services and related legal advice and assistance.

To address the Company’s capital needs, the Company is undergoing efforts to reduce operating expenses and pursuing various equity and debt refinancing and other strategic alternatives, including the sale of certain assets. If the Company is unable to successfully implement its plans or receive adequate relief from its creditors and lessors, the Company would likely to restructure under Chapter 11 of the US Bankruptcy Code. Accordingly, the Company has determined that substantial doubt exists regarding its ability to continue as a going concern as of the date of this filing.

There is no guarantee that the Company will be able to implement its operational plans or raise additional equity or debt financing on acceptable terms, if at all. The condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared on a going concern basis of accounting and these financial statements do not include any adjustments that may result from the outcome of this uncertainty. During the three months ended June 30, 2024, the Company recognized impairment charges related to certain asset groups and abandoned leases related to the triggering events that occurred as further described in Note 5, Goodwill and Other Intangible Assets, Note 6, Property and Equipment, and Note 12, Leases. The impairment analysis involved significant judgment and actual results may differ significantly from our estimates. We may be required to record additional impairment charges in the future.

Reverse Stock Split

On January 31, 2024 (the “Effective Date”), the Company effected a 1-for-30 reverse stock split (the “Reverse Split”) of the Company’s Class A common stock, par value $0.0001 per share (“Class A Common Stock”). As a result of the Reverse Split, every thirty shares of the Class A Common Stock issued and outstanding as of the Effective Date automatically converted into one share of Class A Common Stock. No fractional shares were issued in connection with the Reverse Split. In lieu of issuing fractional shares, stockholders of record who otherwise would have been entitled to receive fractional shares were entitled to rounding up of the fractional share to the nearest whole number. The Reverse Split automatically and proportionately adjusted, based on a 1-for-30 split ratio, all issued and outstanding shares of the Company’s common stock, as well as the terms of warrants outstanding at the time of the effectiveness of the Reverse Split. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of common stock. There was no change in the par value of our Common Stock or Preferred Stock.

References to number of shares of Class A Common Stock and per share data (except par value) in the financial statements and notes thereto for all periods presented have been adjusted to reflect the Reverse Split.

Long-lived Asset Impairments

The Company reviews recoverability of its long-lived assets, including other intangible assets, property and equipment, and right-of-use assets, whenever facts and circumstances indicate that the carrying amount may not be fully recoverable. During the three months ended June 30, 2024, the Company performed an impairment assessment of its asset groups. The impairment assessment was triggered by the rejection by Steward Health Care System of certain contracts, as further explained in section The Business Combination and Acquisitions above. The impairment assessment was also triggered by the Company’s abandonment of a number of leased properties during the three months ended June 30, 2024 and a decision to cease use of additional leased properties following June 30, 2024.

Based on the results of these events and the impairment assessments, the Company recognized impairments of long-lived assets of $133.0 million, consisting of:

•
Property and equipment impairments and finance right-of-use asset abandonments of $25.2 million (Refer to Note 6, Property and Equipment, for further information);
•
Operating right-of-use asset abandonments of $59.0 million (Refer to Note 12, Leases, for further information); and
•
Other intangible asset impairments of $48.8 million (Refer to Note 5, Goodwill and Other Intangible Assets, for further information).

(7)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts and operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions are eliminated upon consolidation. Certain amounts in the prior year’s unaudited condensed consolidated financial statements have been reclassified to conform to the current year presentation.

There is no comprehensive income (loss) so the statements of comprehensive income (loss) are not presented.

Segment Financial Information

The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, regularly reviews financial operating results on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company identifies operating segments based on this review by its CODM and operates in and reports as a single operating segment. For the periods presented, materially all of the Company’s long-lived assets were located in the United States, and all revenue was earned in the United States.

Significant Accounting Policies

Other than the addition of the Impairment of Long-Lived Assets policy, there have been no changes to our significant accounting policies and estimates as described in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 18, 2024.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The areas where significant estimates are used in the financial statements include, but are not limited to, revenues and related receivables from risk adjustments, costs of our services and related liabilities, purchase price allocations, including fair value estimates of intangibles and contingent consideration, the valuation and related impairment testing of long-lived assets, including goodwill and intangible assets, the valuation of derivative liabilities, and the estimated useful lives of fixed assets and intangible assets, including internally developed software. Actual results could differ from those estimates.

Impairment of Long-Lived Assets

Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value.

Fair value estimates used in the impairment review of long-lived assets are determined using a future cash flow model involving several assumptions. Changes in the Company’s assumptions could materially impact fair value estimates. Assumptions critical to our fair value estimates are: (i) projected cash flows and (ii) discount rates. These and other assumptions may change in the future based on specific facts and circumstances. While the Company believes the assumptions used to estimate the future cash flows are reasonable, there can be no assurance that the expected future cash flows will be realized. As a result, impairment charges that possibly would have been recognized in earlier periods may not be recognized until later periods if actual results deviate unfavorably from estimates. The use of different assumptions would increase or decrease discounted cash flows, and therefore could change impairment determinations.

Asset impairment charges are recognized based on the relative fair value of the long-lived assets. Asset impairment charges are recognized in impairments of long-lived assets in the Company’s condensed consolidated statements of operations.

(8)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

Emerging Growth Company

Section 102(b)(1) of the Jumpstart Our Business Startups Act (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies, but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Additionally, as an emerging growth company, the Company is exempt from the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, and the Company’s independent registered public accounting firm is not required to evaluate and report on the effectiveness of internal control over financial reporting.

Accounting Pronouncements Not Yet Adopted

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which is intended to simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The guidance allows for either full retrospective adoption or modified retrospective adoption. The guidance is effective for the Company in the first quarter of fiscal year 2025 and early adoption is permitted. The Company is evaluating the impact the adoption of this guidance will have on its condensed consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures. This guidance requires annual and interim disclosure of significant segment expenses that are provided to the CODM as well as interim disclosures for all reportable segment’s profit or loss and assets. This guidance also requires disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measures of segment profit or loss in assessing segment performance and deciding how to allocate resources. This guidance is expected to improve financial reporting by providing additional information about a public company’s significant segment expenses and more timely and detailed segment information reporting throughout the fiscal period. The ASU is effective for the Company’s fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that adoption of this accounting standard will have on its financial disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The ASU is effective for the Company’s fiscal year beginning January 1, 2025. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that adoption of this accounting standard will have on its financial disclosures.

NOTE 3. ACCOUNTS RECEIVABLE

The Company’s accounts receivable are presented net of the unpaid external provider costs. A right of offset exists when all of the following conditions are met: 1) each of the two parties owed the other determinable amounts; 2) the reporting party has the right to offset the amount owed with the amount owed to the other party; 3) the reporting party intends to offset; and 4) the right of offset is enforceable by law. The Company believes all of the aforementioned conditions existed as of June 30, 2024 and December 31, 2023.

As of June 30, 2024 and December 31, 2023, $44.5 million and $8.9 million of accounts receivable, which were expected to be collected after twelve months, were included in other assets in the Company’s condensed consolidated balance sheets.

(9)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

The Company re-evaluated key assumptions and estimates and based on this analysis, the Company identified changes in estimates to revenue, external provider costs, short-term and long-term accounts receivable, net, and risk settlement liabilities. Accordingly, the Company recognized the following changes in prior year estimates in each respective period (in thousands):

| Six Months Ended June 30, |
Increase (decrease) | 2024 |  |  | 2023 |
Revenue | $ | 8,475 |  |  | $ | (22,964 | )
External provider costs |  | (12,231 | ) |  |  | (1,736 | )
Short-term and long-term accounts receivable, net |  | (926 | ) |  |  | (21,228 | )
Risk settlement liabilities |  | (21,631 | ) |  |  | — |

For the six months ended June 30, 2024, the favorable net development was driven by favorable Medicare risk revenue settlements related to 2023, compared to prior accruals including reserves for risk revenues, and by favorable development in Medicare and Medicaid risk medical expenses relative to prior accruals and provisions for adverse deviation. For the six months ended June 30, 2023, the developments related to the prior year dates of service were primarily driven by new, updated information regarding MSO membership at one health plan, an unseasonably early flu season, and more current data from one Medicaid health plan.

Concentration of Credit Risk

Composition of the Company’s revenues and accounts receivable balances for the payors comprising 10% or more of revenue was as follows (n/a - indicates balance or activity that is less than 10%):

| Revenue
| Three Months Ended June 30, 2024 |  | Six Months Ended June 30, 2024 |  | Three Months Ended June 30, 2023 |  | Six Months Ended June 30, 2023
Payor A | 22% |  | 20% |  | 22% |  | 26%
Payor B | 14% |  | 14% |  | 11% |  | n/a
Payor C | 19% |  | 19% |  | 21% |  | 22%
Payor D | n/a |  | 11% |  | 11% |  | 12%
Payor E | 12% |  | 11% |  | 13% |  | 16%
Payor F | n/a |  | n/a |  | 10% |  | n/a

| Short-Term and Long-Term Accounts Receivable, net
| As of June 30, 2024 |  | As of December 31, 2023
Payor A | n/a |  | 10%
Payor B | n/a |  | 10%
Payor C | n/a |  | n/a
Payor D | n/a |  | n/a
Payor E | n/a |  | n/a
Payor F | 70% |  | 54%

As of June 30, 2024 and December 31, 2023, the Company’s provision for credit losses was $2.8 million a nd $3.1 million, respectively.

NOTE 4. REINSURANCE

The Company purchases stop loss insurance on catastrophic costs to limit the exposure on patient losses. Premiums and policy recoveries are reported in external provider costs in the Company’s condensed consolidated statements of operations.

The intent of the Company’s stop loss coverage is to limit the benefits paid for any individual patient. The Company’s stop loss limits are defined within each respective health plan contract or other third-party contract and range typically from $30,000 to $300,000 per patient per year. Premium expense incurred wa s $7.4 million and $15.3 million for the three and six months ended June 30, 2024, respectively and $6.2 million and $12.9 million for the three and six months ended June 30, 2023, respectively. Physicians under capitation arrangements typically have stop loss coverage so that a physician’s financial risk for any single member is limited to a maximum amount on an annual basis. The Company monitors the financial performance and solvency of its stop loss providers. However, the Company remains financially responsible for health care services to its members in the event the health plans or other third parties are unable to fulfill their obligations under stop loss contractual terms.

(10)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

Recoveries recognized were $3.4 million and $11.2 million for the three and six months ended June 30, 2024, respectively, and $6.3 million and $10.9 million for the three and six months ended June 30, 2023, respectively. Estimated recoveries under stop loss policies are reported within accounts receivable, net, or risk settlement liabilities as the counterparty responsible for the payment of the claims and the stop loss is the respective health plan.

NOTE 5. G OODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

The Company’s policy is to test goodwill for impairment annually on December 31, or on an interim basis if an event triggering impairment may have occurred.

As of June 30, 2024, the Company identified a number of triggering events, including the reduction in the market value of the Company’s Class A Common Stock, and the motion by Steward Health Care System to reject certain of the Company’s provider contracts entered into or acquired as part of the Steward Acquisition. We estimated the fair value of our single reporting unit based on the Company’s market capitalization. In addition, the Company evaluated goodwill for impairment on an enterprise basis by comparing the carrying value of its debt and equity to fair value. As a result of these analyses, the Company concluded that its fair value exceeded its carrying value and no goodwill impairment was identified. The Company estimates that a decrease of up to 30% in the estimated fair value of debt would not result in recognition of goodwill impairment.

As of March 31, 2024, our total shareholders’ equity exceeded our market capitalization. Accordingly, we estimated the fair value of our single reporting unit primarily on the basis of the Company’s market capitalization after considering reasonable control premiums which could be expected in transactions with third-party market participants. Based on this analysis, no goodwill impairment was identified.

As of June 30, 2023, the Company’s market capitalization was below its carrying value, which management believed to be a triggering event requiring an interim goodwill impairment quantitative analysis. Accordingly, the Company performed a market capitalization reconciliation to further evaluate the Company’s estimated fair value balance as of June 30, 2023 and support the implied control premium. Based on the quantitative analysis performed, management concluded that the Company's estimated fair value exceeded its carrying value by approximately $20 million, or 3.0%. Accordingly, no goodwill impairment was recorded during the three months ended June 30, 2023.

As of March 31, 2023, the economic uncertainty and market volatility resulting from the rising interest rate environment, the recent banking crisis and other industry developments resulted in a decrease in the Company’s stock price and market capitalization. Management believed such a decrease was a triggering event requiring an interim goodwill impairment quantitative analysis. The Company performed a market capitalization reconciliation to evaluate the Company’s estimated fair value balance and support the implied control premium. Based on the quantitative analysis performed, the Company’s estimated fair value as of March 31, 2023 was less than its carrying value as of March 31, 2023 by 17.9% or $98.0 million. The $98.0 million goodwill impairment charge has been reflected in goodwill impairment in the accompanying statements of operations during the six months ended June 30, 2023.

The Company’s cumulative goodwill imp airment was $617.2 million as of June 30, 2024 and December 31, 2023.

Other Intangible Assets

The following tables summarize the gross carrying amounts, accumulated amortization and net carrying amounts of intangible assets by major class (in thousands):

|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Impairment Charges |  |  | Net Carrying Value |
June 30, 2024 |  |  |  |  |  |  |  |  |  |  |  |
Risk contracts |  | $ | 102,070 |  |  | $ | (46,073 | ) |  | $ | (23,550 | ) |  | $ | 32,446 |
Provider network |  |  | 42,900 |  |  |  | (10,044 | ) |  |  | (25,228 | ) |  |  | 7,628 |
Non-compete agreements |  |  | 4,170 |  |  |  | (2,753 | ) |  |  | — |  |  |  | 1,417 |
Trademarks |  |  | 1,862 |  |  |  | (1,561 | ) |  |  | — |  |  |  | 301 |
Other |  |  | 693 |  |  |  | (323 | ) |  |  | — |  |  |  | 370 |
Total |  | $ | 151,695 |  |  | $ | (60,754 | ) |  | $ | (48,778 | ) |  | $ | 42,163 |

(11)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Value |
December 31, 2023 |  |  |  |  |  |  |  |  |
Risk contracts |  | $ | 102,070 |  |  | $ | (39,394 | ) |  | $ | 62,676 |
Provider network |  |  | 42,900 |  |  |  | (6,980 | ) |  |  | 35,920 |
Non-compete agreements |  |  | 4,170 |  |  |  | (2,343 | ) |  |  | 1,827 |
Trademarks |  |  | 1,862 |  |  |  | (1,491 | ) |  |  | 371 |
Other |  |  | 693 |  |  |  | (244 | ) |  |  | 449 |
Total |  | $ | 151,695 |  |  | $ | (50,452 | ) |  | $ | 101,243 |

The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying value may not be recoverable. In June 2024, as part of their bankruptcy proceedings, Steward Health Care System moved to reject certain of its contracts with the Company that were entered into or acquired as part of the Steward Acquisition, which served as a triggering event for the MSO asset group. Refer to Note 1, Description of Business and Going Concern, for further information.

Recoverability of long-lived assets to be held and used was measured by comparing the carrying amount of the MSO asset group to the estimated undiscounted future cash flows. The carrying amount exceeded the undiscounted future cash flows and based on further assessment, an impairment charge was recognized for the amount by which the carrying amount of the underlying long-lived assets within the MSO asset group exceeded their fair values. The fair value of the intangible assets was determined using an excess earnings model. During the three and six months ended June 30, 2024, the Company recorded resulting impairment charges of $48.8 million in impairment of long-lived assets in our condensed consolidated statements of operations. There were no other intangible asset impairments recorded during the three and six months ended June 30, 2023.

In addition, the Company reassessed useful lives of the intangible assets included in the MSO asset group, and accelerated amortization of $14.8 million will be recorded prospectively over the estimated remaining useful life of six months.

Amortization expense totaled $5.2 million and $10.3 million for the three and six months ended June 30, 2024, respectively, and $5.7 million and $11.0 million for the three and six months ended June 30, 2023, respectively.

NOTE 6. PROPERTY AND EQUIPMENT

Property and equipment at June 30, 2024 and December 31, 2023 consisted of the following (in thousands):

|  | June 30, 2024 |  |  | December 31, 2023 |
Leasehold improvements |  | $ | 19,691 |  |  | $ | 19,200 |
Vehicles |  |  | 2,614 |  |  |  | 2,892 |
Furniture and equipment |  |  | 11,747 |  |  |  | 12,765 |
Software |  |  | 3,634 |  |  |  | 3,865 |
Assets under finance leases (1) |  |  | — |  |  |  | 18,552 |
Construction in progress |  |  | — |  |  |  | 5,074 |
Total |  |  | 37,686 |  |  |  | 62,349 |
Less: Accumulated depreciation and amortization (2) |  |  | (16,267 | ) |  |  | (14,431 | )
Total Property and equipment, net |  | $ | 21,419 |  |  | $ | 47,918 |

(1) Refer to Note 12, Leases, for information.

(2) Includes accumulated amortization related to finance ROU assets of $1.1 million, $0.6 million as of June 30, 2024 and December 31, 2023, respectively.

Construction in progress primarily consists of leasehold improvements at the Company’s centers, which have not opened.

During the three months ended June 30, 2024, the Company completed a review of its underperforming centers and abandoned certain leased properties. This served as a triggering event for assessment for impairment of the Company’s long-lived asset groups. Refer to Note 1, Description of Business and Going Concern, for further information.

Recoverability of the asset groups was evaluated by comparing the carrying amount of the asset groups to their estimated undiscounted future cash flows. The carrying amount exceeded undiscounted future cash flows and, based on further assessment, an impairment charge was recognized for the amount by which the carrying amount of the underlying long-lived assets exceeded their fair value, which was estimated using the cost recovery method.

In addition, the Company reassessed useful lives of its property and equipment held at the centers which the Company will cease using subsequent to June 30, 2024, and adjusted the estimated useful lives to align with the remaining useful life of the

(12)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

corresponding ROU asset where such assets were utilized. Accordingly, accelerated depreciation of $3.4 million will be recorded prospectively over the estimated remaining useful life of six months.

As a result of these analyses, the Company recorded non-lease related property and equipment impairment charges of $7.1 million and finance lease abandonment charges of $18.1 million both within impairments of long-lived assets in our condensed consolidated statements of operations in the three and six months ended June 30, 2024. There were no property and equipment impairments or lease abandonments recorded during the three and six months ended June 30, 2023.

Depreciation expense, including amortization related to finance lease ROU assets, totaled $1.4 million and $2.9 million for the three and six months ended June 30, 2024, respectively, and $1.2 million and $2.4 million for the three and six months ended June 30, 2023, respectively.

NOTE 7. DEBT AND RELATED PARTY DEBT

Credit Agreement

In May 2022, the Company entered into a credit agreement (the “Credit Agreement”) that provided for an aggregate of up to $300.0 million in term loans, comprised of (i) initial term loans in the aggregate principal amount of $190.0 million (the “Initial Term Loans”) and (ii) a delayed term loan facility in the aggregate principal amount of $110.0 million (the “Delayed Draw Term Loans”). The Credit Agreement permits the Company to enter into certain incremental facilities subject to compliance with the terms, conditions and covenants set forth therein. In May 2022, the Company drew $190.0 million of the Initial Term Loans and used approximately $121 million of the net proceeds from this borrowing to repay its outstanding obligations under the credit agreement dated June 8, 2021, as amended and recognized related debt extinguishment losses of $6.2 million.

The Credit Agreement contains certain covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, liens or encumbrances, to make certain investments, to enter into sale-leaseback transactions or sell certain assets, to make certain restricted payments or pay dividends, to enter into consolidations, to transact with affiliates and to amend certain agreements, subject in each case to the exceptions and other qualifications as provided in the Credit Agreement. The Credit Agreement also contains covenants that require the Company to satisfy a minimum liquidity requirement of $50.0 million, which may be decreased to $25.0 million if the Company achieves a certain adjusted EBITDA, and maintain a maximum total leverage ratio based on the Company’s consolidated EBITDA, as defined in the Credit Agreement, with de novo losses excluded from the calculation of such ratio for up to 36 months after the opening of a de novo center, which maximum total leverage ratio was initially 8.50 to 1.00, commencing with the fiscal quarter ended September 30, 2022 and is subject to a series of step-downs. For the fiscal quarters ending September 30, 2026 and thereafter the Company must maintain a maximum total leverage ratio no greater than 5.50 to 1.00.

The Credit Agreement contains embedded derivatives related to optional and mandatory prepayments, default interest and the impact of potential legislative changes. Embedded derivatives are separated from the host contract, and are carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument. The Company has concluded that mandatory prepayment and default interest features within the Credit Agreement meet these criteria and, as such, are valued separately and apart from the Credit Agreement and are recorded at fair value each reporting period. The value of such bifurcated derivatives was $0 as of June 30, 2024 and December 31, 2023. Changes in the fair value of these derivatives are reflected in the Change in fair value of derivative liabilities within the condensed consolidated statements of operations and the fair value of the derivatives as of June 30, 2024 is reflected in other current liabilities within the condensed consolidated balance sheets. Refer to Note 10, Fair Value Measurements, for information about the valuation of the embedded derivatives.

On March 8, 2023 (the “Amendment Closing Date”), the Company entered into a Second Amendment (the “Second Amendment”) to the Credit Agreement. The Second Amendment amended the Credit Agreement to, among other things, (i) provide for a new incremental delayed draw term loan B facility in an aggregate principal amount of $60.0 million (the “Delayed Draw Term Loan B Facility”); (ii) revise the commitment expiration date for the Company’s existing $110.0 million Delayed Draw Term Loan to forty-five days following the Amendment Closing Date; (iii) extend the commencement of amortization payments on loans under the Credit Agreement from March 31, 2024 to May 31, 2025; (iv) reduce the amount of interest that the Company may elect to capitalize from 4.00% to 3.50% beginning on the second anniversary of the execution date of the Credit Agreement, 3.00% beginning on the third anniversary of the execution date of the Credit Agreement, and 1.50% beginning on December 10, 2025; (v) increase the amount of the super-priority revolving credit facility that is permitted

(13)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

to be added to the Credit Agreement to $45.0 million and provide that the entirety of such facility may be used for general corporate purposes; and (vi) amend the prepayment provisions of the Credit Agreement, including to have such provisions run as of the Amendment Closing Date.

On March 15, 2024, the Company entered into a Waiver and Third Amendment to the Credit Agreement (the “Third Amendment”). The Third Amendment amended the Credit Agreement to, among other things, (i) waive certain events of default under the Credit Agreement in the limited manner set forth therein through May 15, 2024 (the “Third Amendment Specified Period”), subject to an earlier termination of the waiver upon the occurrence of certain specified events, (ii) increase the applicable margin rate by 2.00% during the Third Amendment Specified Period, which additional interest the Company may elect to capitalize as principal amount on the outstanding loans and (iii) modify certain covenants contained in the Credit Agreement, including, but not limited to, reducing the minimum liquidity requirement to $10 million during the Third Amendment Specified Period and providing for additional reporting to the lenders.

On May 14, 2024, the Company entered into a Limited Waiver and Fourth Amendment to the Credit Agreement (the “Fourth Amendment”). The Fourth Amendment amended the Credit Agreement to, among other things, extend the waiver of certain events of default under the Credit Agreement in the limited manner set forth therein through June 17, 2024 (the “Temporary Waiver Period”), subject to an earlier termination of the waiver upon the occurrence of certain specified events.

On June 17, 2024, the Company entered into a Limited Waiver and Fifth Amendment to the Credit Agreement (the “Fifth Amendment”). The Fifth Amendment amended the Credit Agreement to extend the waiver of certain events of default under the Credit Agreement in the limited manner set forth therein through June 24, 2024, subject to an earlier termination of the waiver upon the occurrence of certain specified events.

On June 21, 2024, the Company entered into a Limited Waiver and Sixth Amendment to the Credit Agreement (the “Sixth Amendment”). The Sixth Amendment amended the Credit Agreement to extend the waiver of certain events of default under the Credit Agreement in the limited manner set forth therein through June 28, 2024, subject to an earlier termination of the waiver upon the occurrence of certain specified events.

On June 28, 2024, the Company entered into a Limited Waiver and Seventh Amendment to the Credit Agreement (the “Seventh Amendment”). The Seventh Amendment amended the Credit Agreement to extend the waiver of certain events of default under the Credit Agreement in the limited manner set forth therein through July 8, 2024, subject to an earlier termination of the waiver upon the occurrence of certain specified events.

Refer to Note 16, Subsequent Events, for information about the Extended Seventh and the Eighth Amendments the Company entered into in July 2024.

During the six months ended June 30, 2024 and 2023, the Company drew $0 and $65.0 million of the Delayed Draw Term Loans, respectively.

Based on the elections made by the Company, as of June 30, 2024, b orrowings under the Credit Agreement bore interest of Term SOFR (calculated as the Secured Overnight Financing Rate published on the Federal Reserve Bank of New York’s website, plus the applicable credit spread adjustment based on the elected interest period), plus an applicable margin rate of 11.00%. As permitted under the Credit Agreement, as amended, the Company elected to capitalize the full amount of interest as principal from March 15, 2024 through August 15, 2024. As a result of this election, the cash interest component of the applicable margin increased by 2.00%.

Loan and Security Agreement - Related Party Debt

In November 2022, the Company entered into a Loan and Security Agreement (the “Loan and Security Agreement”), by and among Sparta Merger Sub I Inc., a Delaware corporation and wholly-owned subsidiary of the Company, Sparta Merger Sub II Inc., a Delaware corporation and wholly-owned subsidiary of the Company, Sparta Merger Sub I LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (“Merger LLC I”), Sparta Merger Sub II LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (together with Merger LLC I, the “Guarantors”), Steward Accountable Care Network, Inc. (n/k/a as Steward Accountable Care Network, LLC) and Steward National Care Network, Inc. (n/k/a Steward National Care Network, LLC), as borrowers (the “Borrowers”), CAJ Lending LLC (“CAJ”) and Deerfield Partners L.P., as lenders (the “Lenders”), and CAJ, as administrative agent and collateral agent (in such capacity, the “Agent”). Mr. Carlos A. de Solo, a director of the Company and the Company’s President and Chief Executive Officer, Mr.

(14)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

Alberto de Solo, the Company’s Executive Vice President and Chief Operating Officer, and Mr. Joseph N. De Vera, the Company’s Senior Vice President and Legal Counsel, have interests in CAJ.

Pursuant to the Loan and Security Agreement, the Lenders provided the Borrowers a term loan (the “Term Loan”) in the aggregate principal amount of $35.5 million. The Company used the proceeds of the Term Loan to fund the payment for the estimated value of the accounts receivable attributable to Medicare value-based payments for the period between January 1, 2022 and the closing of the Steward Acquisition, minus the amount of such payments payable to the affiliate physicians of the acquired Steward entities (the “Financed Net Pre-Closing Medicare AR”).

The Term Loan bore fixed interest at a rate of 12.0% per annum. In addition, the Borrowers paid a facility fee equal to 3.0% of the aggregate principal amount of the Term Loan, which was accounted for as a debt discount. Any additional interest (if applicable) accrued and owing during the term of the Loan and Security Agreement was paid-in-kind and capitalized to principal monthly in arrears. Pursuant to the Agreement and Plan of Merger entered into in connection with the Steward Acquisition (the “Merger Agreement”), Sparta Holding Co. LLC agreed to pay the costs of financing the Financed Net Pre-Closing Medicare AR and, at the closing of the Steward Acquisition, paid to the Borrowers $6.8 million, representing all scheduled payments of interest and fees from the Steward Acquisition closing date up to and including November 30, 2023, which amount was then paid in advance by the Borrowers to the Lenders.

In October 2023, the Company paid off all outstanding indebtedness of $35.5 million due under the Loan and Security Agreement with the proceeds of the MSSP payment from the federal government, and the Loan and Security Agreement was terminated.

Elevance Health

In October 2022, in connection with the collaboration agreement with Elevance Health (formerly known as Anthem) the Company entered into a promissory note for $1.0 million due in October 2032. This borrowing bears a fixed interest rate of 6.25% per annum.

Finance Leases

Refer to Note 12, Leases, for information about the Company’s finance leases.

As of June 30, 2024 and December 31, 2023, debt consisted of the following (in thousands):

|  | June 30, 2024 |  |  | December 31, 2023 |
Indebtedness under the Credit Agreement, weighted-average interest rate of 15.2% during the six months ended June 30, 2024. |  | $ | 399,295 |  |  | $ | 377,340 |
Finance lease obligations, interest averaging 13.5% and maturing at various dates through 2043 as of June 30, 2024 and December 31, 2023. |  |  | 15,148 |  |  |  | 19,612 |
Other |  |  | 2,189 |  |  |  | 2,220 |
Less: Unamortized discounts and debt issuance costs |  |  | (11,528 | ) |  |  | (13,349 | )
|  |  | 405,105 |  |  |  | 385,823 |
Less: Current portion |  |  | (403,321 | ) |  |  | (364,380 | )
Long-term portion |  | $ | 1,785 |  |  | $ | 21,443 |

Future maturities of the indebtedness outstanding at June 30, 2024 were as follows (in thousands):

Year |  | Amount |
Remainder of 2024 |  | $ | 214 |
2025 |  |  | 3,700 |
2026 |  |  | 4,333 |
2027 |  |  | 392,309 |
2028 |  |  | 769 |
Thereafter |  |  | 160 |
Total |  | $ | 401,485 |

In the table above, the future maturities are presented consistent with the contractual terms. As of June 30, 2024, we were in compliance with all of the financial covenants under the Credit Agreement, as amended through the Seventh Amendment; however, without an additional waiver, we do not expect to be in compliance during the subsequent quarterly testing dates. A breach of any of the covenants under the Credit Agreement or the occurrence of other events specified in the Credit Agreement

(15)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

could result in an event of default under the same and give rise to the lenders’ right to accelerate our debt obligations thereunder and pursue other remedial actions under such agreement and/or trigger a cross default under our long-term leases. Accordingly, as of June 30, 2024, the full balance of the outstanding indebtedness related to the Credit Agreement was classified as a current liability in our condensed consolidated balance sheet.

Refer to Note 1, Description of Business and Going Concern, for going concern considerations.

NOTE 8. STOCK-BASED COMPENSATION

The Company’s 2021 Long-Term Incentive Plan (the “2021 Plan”) permits the grant of equity-based awards to officers, directors, employees and other service providers. The 2021 Plan permits the grant of an initial share pool of 233,333 shares of Class A Common Stock and will be increased automatically, without further action of the Company’s board of directors, on January 1st of each calendar year commencing after the Closing Date and ending on (and including) January 1, 2031, by a number of shares of Class A Common Stock equal to the lesser of (i) four percent of the aggregate number of shares of Class A Common Stock outstanding on December 31st of the immediately preceding calendar year, excluding for this purpose any such outstanding shares of Class A Common Stock that were granted under the 2021 Plan and remain unvested and subject to forfeiture as of the relevant December 31st, or (ii) a lesser number of shares of Class A Common Stock as determined by the Company’s board of directors or the Compensation Committee of the board of directors prior to the relevant January 1st.

Our outstanding stock-based compensation awards consist of time-based share awards, performance-based share awards and options. Our equity awards generally vest over a three-year period, subject to continued provision of services to the Company through the applicable vesting date.

During the six months ended June 30, 2024, no equity awards were granted, and 44,428 shares of previously issued awards vested. During the six months ended June 30, 2023, 111,018 shares of equity awards were granted and 30,165 shares of previously issued awards vested.

During the three and six months ended June 30, 2024 and 2023, the Company recognized stock-based compensation expense totaling $2.4 million, $4.8 million, $2.5 million and $4.8 million, respectively. As of June 30, 2024 and 2023, total unrecognized compensation expense related to unvested equity awards was $9.0 million and $25.1 million, respectively, expected to be recognized over a weighted-average period of 1.5 years and 2.9 years, respectively.

NOTE 9. NET LOSS PER SHARE

The following table sets forth the calculation of basic and diluted net loss per share for the periods indicated based on the weighted-average number of common shares outstanding (in thousands, except share and per share data):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Net loss attributable to CareMax, Inc. Class A common stockholders |  | $ | (170,558 | ) |  | $ | (32,376 | ) |  | $ | (213,966 | ) |  | $ | (114,458 | )
Weighted-average basic shares outstanding |  |  | 3,807,551 |  |  |  | 3,722,377 |  |  |  | 3,793,076 |  |  |  | 3,717,040 |
Weighted-average diluted shares outstanding |  |  | 3,807,551 |  |  |  | 3,722,377 |  |  |  | 3,793,076 |  |  |  | 3,717,040 |
Net loss per share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | (44.79 | ) |  | $ | (8.70 | ) |  | $ | (56.41 | ) |  | $ | (30.79 | )
Diluted |  | $ | (44.79 | ) |  | $ | (8.70 | ) |  | $ | (56.41 | ) |  | $ | (30.79 | )

The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive or because issuance of shares underlying such securities is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the period:

(16)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Series A and Series B warrants |  |  | 266,667 |  |  |  | 266,667 |  |  |  | 266,667 |  |  |  | 266,667 |
Public and private placement warrants |  |  | 193,055 |  |  |  | 193,055 |  |  |  | 193,055 |  |  |  | 193,055 |
Contingent consideration |  |  | 1,250,000 |  |  |  | 1,321,111 |  |  |  | 1,250,000 |  |  |  | 1,338,889 |
Unvested restricted stock units |  |  | 88,326 |  |  |  | 114,006 |  |  |  | 96,207 |  |  |  | 116,096 |
Unvested performance stock units (assumes 100% target payout) |  |  | 12,659 |  |  |  | 12,105 |  |  |  | 13,456 |  |  |  | 12,105 |
Unvested options |  |  | 19,830 |  |  |  | 18,732 |  |  |  | 21,557 |  |  |  | 18,732 |
Total |  |  | 1,830,536 |  |  |  | 1,925,676 |  |  |  | 1,840,942 |  |  |  | 1,945,544 |

NOTE 10. FAIR VALUE MEASUREMENTS

Financial Instruments that are Measured at Fair Value on a Recurring Basis

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value (in thousands):

|  |  |  |  | Fair Value |
June 30, 2024 |  |  |  |  | Quoted Prices in Active Markets |  |  | Significant other Observable Units |  |  | Significant other Unobservable Units |
Description |  | Carrying Value |  |  | (Level 1) |  |  | (Level 2) |  |  | (Level 3) |
Derivative warrant liabilities - public warrants |  | $ | 48 |  |  | $ | 48 |  |  | $ | — |  |  | $ | — |
Total liabilities measured at fair value |  | $ | 48 |  |  | $ | 48 |  |  | $ | — |  |  | $ | — |
|  |  |  |  | Fair Value |
December 31, 2023 |  |  |  |  | Quoted Prices in Active Markets |  |  | Significant other Observable Units |  |  | Significant other Unobservable Units |
Description |  | Carrying Value |  |  | (Level 1) |  |  | (Level 2) |  |  | (Level 3) |
Derivative warrant liabilities - public warrants |  | $ | 22 |  |  | $ | 22 |  |  | $ | — |  |  | $ | — |
Derivative warrant liabilities - private placement warrants |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 1 |
Total liabilities measured at fair value |  | $ | 22 |  |  | $ | 22 |  |  | $ | — |  |  | $ | 1 |

Derivative Warrant Liabilities

Fair value of public warrants is measured using the listed market price of such warrants.

Fair value of the private placement warrants is estimated using a Monte Carlo simulation model at each measurement date. Inherent in a Monte Carlo simulation are assumptions related to expected stock price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock based on historical volatility of select peer companies that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.

During the three and six months ended June 30, 2024, the Company recognized loss of less than $0.1 million related to the change in the fair value of the derivative warrant liabilities. During the three and six months ended June 30, 2023, the Company recognized a benefit of $0.4 million and $1.5 million, respectively, related to the change in the fair value of the derivative warrant liabilities.

Credit Agreement Embedded Derivatives

Fair value of the embedded derivatives contained in the Credit Agreement is estimated using the discounted cash flow model. This involves significant Level 3 inputs and assumptions including the probability of occurrence of the respective triggering events and our risk-adjusted discount rate. During the three and six months ended June 30, 2024, the Company recognized a benefit of $2.4 million and $0, respectively, related to the change in the fair value of the Credit Agreement embedded

(17)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

derivatives. During the three and six months ended June 30, 2023, the Company recognized $0 in both periods related to the change in the fair value of the Credit Agreement embedded derivatives. As of June 30, 2024, the carrying value of the embedded derivatives was $0.

Transfers between level 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the three and six months ended June 30, 2024 or 2 0 23.

Activity of the Level 3 liabilities during the six months ended June 30, 2024 measured at fair value was as follows (in thousands):

Balance as of December 31, 2023 | $ | 1 |
Change in fair value of derivative warrant liabilities |  | (1 | )
Balance as of June 30, 2024 | $ | — |

Activity of the Level 3 liabilities during the six months ended June 30, 2023 measured at fair value was as follows (in thousands):

Balance as of December 31, 2022 | $ | 137,040 |
Change in fair value of derivative warrant liabilities |  | (1,167 | )
Change in fair value of contingent consideration |  | (19,916 | )
Reclassification of contingent earnout consideration previously liability classified |  | (114,645 | )
Balance as of June 30, 2023 | $ | 1,313 |

Financial Instruments that are not Measured at Fair Value on a Recurring Basis

Debt

|  |  |  |  | Fair Value |
June 30, 2024 |  | Carrying Value |  |  | Quoted Prices in Active Markets |  |  | Significant other Observable Units |  |  | Significant other Unobservable Units |
(in thousands) |  |  |  |  | (Level 1) |  |  | (Level 2) |  |  | (Level 3) |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Fixed rate debt (a) |  | $ | 873 |  |  | $ | — |  |  | $ | — |  |  | $ | 575 |
Floating rate debt (a) |  |  | 399,295 |  |  |  | — |  |  |  | — |  |  |  | 364,579 |
Total |  | $ | 400,169 |  |  | $ | — |  |  | $ | — |  |  | $ | 365,153 |
|  |  |  |  | Fair Value |
December 31, 2023 |  | Carrying Value |  |  | Quoted Prices in Active Markets |  |  | Significant other Observable Units |  |  | Significant other Unobservable Units |
(in thousands) |  |  |  |  | (Level 1) |  |  | (Level 2) |  |  | (Level 3) |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Fixed rate debt (a) |  | $ | 913 |  |  | $ | — |  |  | $ | — |  |  | $ | 747 |
Floating rate debt (a) |  |  | 377,340 |  |  |  | — |  |  |  | — |  |  |  | 375,240 |
Total |  | $ | 378,253 |  |  | $ | — |  |  | $ | — |  |  | $ | 375,987 |

(a) The debt amounts above do not include the impact of debt issuance costs or discounts.‌

Impairment of Long-Lived Assets

As part of its impairment assessment of the long-lived assets as of June 30, 2024, the Company remeasured certain long-lived assets to fair value on a non-recurring basis, which resulted in impairments recorded to impairment of long-lived assets in its condensed consolidated statements of operations. The impairments were determined by comparing the fair value of the impacted asset groups to their carrying value as of June 30, 2024, as required under ASC Topic 360, Property, Plant, and Equipment, and ASC Topic 350, Intangibles - Goodwill and Other, using Level 3 inputs.

Refer to Note 1, Description of Business and Going Concern, Note 5, Goodwill and Other Intangible Assets, Note 6, Property and Equipment, and Note 12, Leases, for further information.

NOTE 11. R ELATED PARTY TRANSACTIONS

(18)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

The Related Companies

In 2021, the Company entered into an exclusive real estate advisory agreement (the “Advisory Agreement”) with Related CM Advisor, LLC (the “Advisor”), a Delaware limited liability company and a subsidiary of The Related Companies, L.P. (“Related”) (the “Advisory Agreement”), purs uant to which the Advisor has agreed to provide certain real estate advisory services to the Company on an exclusive basis. In connection with the Advisory Agreement, the Company issued certain warrants to the Advisor which vested at the time of issuance, and additional 5,000,000 warrants, which will vest and become exercisable from time to time upon the opening of each center under the Advisory Agreement for which the Advisor provides services. As of June 30, 2024 and December 31, 2023, 3,500,000 Advisory Agreement warrants remained unvested.

During the three and six months ended June 30, 2024 and 2023, the Company recognized $0.1 million and $0.2 million, and $0 and $0, respectively, of expense related to the amortization of the vested Advisory Agreement warrants, in corporate, general and administrative expenses.

As of June 30, 2024 and December 31, 2023, the Company recorded $0.4 million in other current assets, related to the Advisory Agreement warrants.

On July 13, 2021, the Board appointed Mr. Bryan Cho, Executive Vice President of Related, to serve as a Class III director of the Company. The appointment of Mr. Cho was made in connection with the Advisory Agreement, which provides the Advisor with the right to designate a director to serve on the Board, subject to the continuing satisfaction of certain conditions, including that the Advisor and its affiliates maintain ownership of at least 16,667 shares of Class A Common Stock. As a director of the Company, Mr. Cho receives compensation in the same manner as the Company’s other non-employee directors.

Steward Health Care System, LLC

In November 2022, as part of the Steward Acquisition, the Board appointed Dr. Ralph de la Torre, Chairman, Chief Executive Officer and principal equity holder of Steward Health Care System, LLC (“Steward Health Care System”) as a director of the Company. Dr. de la Torre receives compensation in the same manner as the Company’s other non-employee directors.

As part of the Steward Acquisition, the aggregate consideration to the Seller included contingent earnout consideration, which has not been issued to the Seller as of June 30, 2024. Refer to Note 4, Acquisitions, in the notes of the consolidated financial statements in the Company’s 2023 Form 10-K for details related to the contingent earnout consideration.

During the three and six months ended June 30, 2024, the Company incurred expenses related to the transition services agreement with Steward Health Care System of $0 and $0.2 million, respectively, within corporate, general and administrative expenses. During the three and six months ended June 30, 2023, the Company incurred expenses related to a transition services agreement with Steward Health Care System of $0.3 million and $1.0 million, respectively, within corporate, general and administrative expenses.

As of June 30, 2024 and December 31, 2023, the Company had liabilities due to Steward Health Care System, or its affiliates, of $1.7 million and $0.2 million, respectively.

CAJ and Deerfield

In November 2022, the Company entered into the Loan and Security Agreement, described in Note 7, Debt and Related Party Debt, whereby CAJ and Deerfield are the lenders. In October 2023, the Company paid off all outstanding indebtedness of $35.5 million due under the Loan and Security Agreement with the proceeds of the MSSP payment from the federal government, and the Loan and Security Agreement was terminated.‌

Mr. Carlos A. de Solo, a director of the Company and the Company’s President and Chief Executive Officer, Mr. Alberto de Solo, the Company’s Executive Vice President and Chief Operating Officer, and Mr. Joseph N. De Vera, the Company’s Senior Vice President and Legal Counsel, have interests in CAJ.

Mr. Kevin Berg, who is on the Board, is a Senior Advisor with Deerfield. As a director of the Company, Mr. Berg receives compensation in the same manner as the Company’s other non-employee directors.‌

(19)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

NOTE 12. LEASES

The Company has entered into operating and finance lease agreements for centers and office space expiring at various times through 2043, inclusive of renewal options that the Company is reasonably certain to exercise. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease.

The following table presents the location of the finance lease ROU assets and lease liabilities in the Company’s condensed consolidated balance sheets (in thousands):

| Condensed Consolidated Balance Sheet Line Item |  | June 30, 2024 |  |  | December 31, 2023 |
Finance lease right-of-use assets, net | Property and equipment, net 1 |  | $ | — |  |  | $ | 18,552 |
Current finance lease liabilities | Current portion of third-party debt, net 2 |  |  | 15,148 |  |  |  | — |
Long-term finance lease liabilities | Long-term debt, net |  |  | — |  |  |  | 19,612 |
1 Carrying value as of June 30, 2024, reflects impairments further described in Note 6, Property and Equipment. |
2 Classification of finance lease liabilities as current reflects the acceleration of payments due in relation to finance leases in default as of June 30, 2024. Refer to Lease Default and Abandonment below for further information. |

Lease costs were as follows (in thousands):

|  |  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| Condensed Consolidated Statements of Operations Location |  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Operating lease cost | Corporate, general and administrative |  | $ | 4,533 |  |  | $ | 4,873 |  |  | $ | 8,437 |  |  | $ | 9,175 |
Finance lease cost: |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization of lease assets | Depreciation and amortization |  |  | 240 |  |  |  | — |  |  |  | 480 |  |  |  | — |
Interest on lease liabilities | Interest expense |  |  | 661 |  |  |  | — |  |  |  | 1,317 |  |  |  | — |
Variable lease cost | Corporate, general and administrative |  |  | 1,019 |  |  |  | 823 |  |  |  | 2,188 |  |  |  | 1,491 |
Short-term lease cost | Corporate, general and administrative |  |  | 285 |  |  |  | 344 |  |  |  | 563 |  |  |  | 625 |
Total lease cost |  |  | $ | 6,737 |  |  | $ | 6,040 |  |  | $ | 12,984 |  |  | $ | 11,291 |

As of June 30, 2024, maturities of operating and finance lease liabilities were as follows (in thousands):

Year |  | Operating Leases |  |  | Finance Leases |
Remainder of 2024 |  | $ | 8,637 |  |  | $ | 1,177 |
2025 |  |  | 16,181 |  |  |  | 2,499 |
2026 |  |  | 15,668 |  |  |  | 2,549 |
2027 |  |  | 14,669 |  |  |  | 2,625 |
2028 |  |  | 13,606 |  |  |  | 2,704 |
Thereafter |  |  | 110,392 |  |  |  | 48,944 |
Total undiscounted lease obligations |  |  | 179,152 |  |  |  | 60,498 |
Less: Present value discount |  |  | (71,051 | ) |  |  | (40,592 | )
Present value of lease liabilities |  | $ | 108,101 |  |  | $ | 19,905 |

Lease Default and Abandonment

During the three months ended June 30, 2024, the Company completed an operational review of its underperforming centers and subsequently abandoned 5 finance leased properties, 15 operating leased properties and 5 leased properties where the leases had not yet commenced or were short-term in nature. The Company ceased rent payments for these properties, which in most cases constituted events of default under the related lease agreements. Upon an event of default, remedies available to our landlords generally include, without limitation, terminating such lease agreement, repossessing and reletting the leased properties and requiring us to remain liable for all obligations under such lease agreement, including the difference between the rent under such lease agreement and the rent payable as a result of reletting the leased properties, or requiring us to pay the rent due for the balance of the term of such lease agreement, less proceeds from re-letting, if any. As a result of these defaults,

(20)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

as of June 30, 2024, operating lease liabilities of $34.5 million were reclassified to current portion of operating lease liabilities, and finance lease liabilities of $19.9 million were reclassified to current portion of third-party debt, net, in the Company’s condensed consolidated balance sheets.

In addition to the leases abandoned as of June 30, 2024, and as further explained in Note 1, Description of Business and Going Concern, the Company decided to cease use of additional leased properties following June 30, 2024. These leases were considered in the long-lived asset impairment analyses, as well as through the Company assessing the remaining useful lives of these assets, as further described in Note 1, Description of Business and Going Concern. The Company recognized $59.0 million and $18.1 million of abandonment charges on operating and finance right-of-use assets, respectively, abandoned as of June 30, 2024, in impairment of long-lived assets in the condensed consolidated statements of operations for the three and six month periods ended June 30, 2024.

Additionally, the Company identified certain additional operating leased properties, which it plans to abandon after June 30, 2024, and for which no impairment was recorded. The Company reassessed remaining useful lives for these properties and the related accelerated amortization of $13.1 million will be recorded prospectively over the estimated remaining useful life of six months.

Other information related to lease agreements was as follows:

|  | June 30, 2024 |  | December 31, 2023
Weighted-average remaining lease term (years) |  |  |  |
Operating leases |  | 11.7 |  | 11.7
Finance leases |  | 18.8 |  | 19.3
Weighted-average discount rate |  |  |  |
Operating leases |  | 8.79% |  | 8.16%
Finance leases |  | 13.46% |  | 13.46%
Cash paid for amounts included in measurement of liabilities (in thousands) |  |  |  |
Operating cash flows for operating leases |  | 5,028 |  | 12,605
Operating cash flows for finance leases |  | 1,317 |  | 1,310

At June 30, 2024, the Company was party to leases that have not yet commenced with aggregated estimated future lease payments of approximately $24.8 million, which are not reflected in the above tables.

The Company’s finance leases, two of the operating leases, and one lease that has not yet commenced, contain various covenants, that require the Company, among other things, to maintain minimum consolidated stockholder's equity of $100.0 million and a minimum cash balance of $25.0 million. In addition, these leases are subject to provisions that provide for a cross default in the event any of covenant violations under the Company’s Credit Agreement or in the event that covenant violations occur in other lease agreements with the same landlord.

NOTE 13. INCOME TAXES

Income tax expense was $0.2 million and $0.4 million during the three and six months ended June 30, 2024, respectively and $0.2 million and $0.4 million during the three and six months ended June 30, 2023, respectively. The effective tax rate was (0.1)% and (0.2)%, during the three and six months ended June 30, 2024, respectively, and (0.6)% and (0.3)% during the three and six months ended June 30, 2023, respectively, based on the assessment of a full valuation allowance, excluding a portion attributable to the “naked credit” deferred tax liability.

(21)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

NOTE 14. COMMITMENTS AND CONTINGENCIES

Compliance

The health care industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with imposition of significant fines and penalties, as well as significant repayments for patient services billed. Compliance with these laws and regulations, specifically those related to the Medicare and Medicaid programs, can be subject to government review and interpretation, as well as regulatory actions unknown and not yet asserted at this time. Management believes that the Company is in substantial compliance with current laws and regulations.

Litigation

From time to time, the Company is involved in various legal actions, demands, claims, qui tam suits, governmental investigations and audits, and other legal matters arising in the normal course of business. Except as described below, management has not identified any legal actions during the three and six months ended June 30, 2024 or 2023 that were deemed to be material.

As described above in Note 12, Leases, during the three and six months ended June 30, 2024, the Company failed to make rent payments due pursuant to certain of its center leases on centers that the Company generally does not intend to operate, which resulted in an event of default under the terms of the related lease agreements. Landlords of certain of the Company’s leased centers for which the Company failed to pay rent have filed lawsuits against the Company for default on the lease payments. During the three and six months ended June 30, 2024, total lease liabilities related to such leases were classified as a current liability in the Company’s condensed consolidated balance sheets.

NOTE 15. VAR IABLE INTEREST ENTITIES

The Company has Administrative Service Agreements (the “ASAs”) with Medical Care of NY, P.C., Medical Care of Tennessee, PLLC and Medical Care of Texas, PLLC (together, the “PCs”), which were established to employ healthcare providers to deliver healthcare services to patients in New York, Tennessee, and Texas, and with Care Optical, LLC (“Care Optical”), which provides optometry services in the state of Florida. The Company concluded that it has variable interest in the PCs and Care Optical on the basis of its ASAs which provide for a management fee payable to the Company from the PCs and Care Optical in exchange for providing management and administrative services which creates risk and a potential return to the Company. The PCs’ and Care Optical’s equity at risk, as defined by GAAP, is insufficient to finance their activities without additional support, and therefore, the PCs and Care Optical are considered to be VIEs.

In order to determine whether the Company has a controlling financial interest in the PCs and Care Optical, and, thus, is the PCs’ and Care Optical’s primary beneficiary, the Company considered whether it has (i) the power to direct the activities of PCs and Care Optical that most significantly impacts their economic performance and (ii) the obligation to absorb losses of the PCs and Care Optical or the right to receive benefits from the PCs and Care Optical that could potentially be significant to them. The Company concluded that the member and employees of the PCs and Care Optical have no individual power to direct activities of the PCs and Care Optical that most significantly impact their economic performance. Under the ASAs, the Company is responsible for providing services that impact the growth of the patient population of the PCs and Care Optical, the management of the respective population’s healthcare needs, the provision of required healthcare services to those patients, and the PCs’ and Care Optical’s ability to receive revenue from health plans. In addition, the Company’s variable interest in the PCs and Care Optical provides the Company with the right to receive benefits that could potentially be significant to them. The single members of the PCs and Care Optical are employees of the Company. Based on this analysis, the Company concluded that it is the primary beneficiary of the PCs and Care Optical and therefore consolidates the balance sheet, results of operations and cash flow of the PCs and Care Optical.

Furthermore, as a direct result of nominal initial equity contributions by the single members of the PCs and Care Optical, the financial support CareMax provides to the PCs and Care Optical (e.g. loans) and the provisions of the arrangements described above, the interest held by the single member lacks economic substance and does not provide the member with the ability to

(22)

CAREMAX, inc.

NOTES TO condensed consolidated FINANCIAL STATEMENTS

(Unaudited)

participate in the residual profits or losses generated by the PCs and Care Optical. Therefore, all income and expenses recognized by the PCs and Care Optical are allocated to CareMax.

The following tables summarize the financial position and operations of the PCs and Care Optical (in thousands):

| June 30, 2024 |  |  | December 31, 2023 |
Total assets | $ | 1,032 |  |  | $ | 1,200 |
Total liabilities | $ | 12,092 |  |  | $ | 9,896 |

| Three Months Ended June 30, 2024 |  |  | Six Months Ended June 30, 2024 |  |  | Three Months Ended June 30, 2023 |  |  | Six Months Ended June 30, 2023 |
Revenue | $ | 1,101 |  |  | $ | 1,975 |  |  | $ | 580 |  |  | $ | 997 |
Operating expenses | $ | 1,975 |  |  | $ | 3,702 |  |  | $ | 1,977 |  |  | $ | 3,691 |

NOTE 16. SUBSEQUENT EVENTS

On July 8, 2024, the Company entered into an Extended Limited Waiver and Seventh Amendment to the certain Credit Agreement (the “Extended Seventh Amendment”). The Extended Seventh Amendment amended the Credit Agreement to extend the waiver of certain events of default under the Credit Agreement in the limited manner set forth therein through July 10, 2024, subject to an earlier termination of the waiver upon the occurrence of certain specified events.

On July 10, 2024, the Company entered into a Limited Waiver and Eighth Amendment to the Credit Agreement (the “Eighth Amendment”). The Eighth Amendment amended the Credit Agreement to, among other things, provide for a new $4.0 million term loan (the “Eighth Amendment Term Loan”), funded at the closing of the Eighth Amendment, and a new incremental delayed draw term loan facility in an aggregate principal amount of $16.0 million, funded at the discretion of the Lenders (the loans thereunder, “Delayed Draw Term Loans” and, together with the Eighth Amendment Term Loan, the “Eighth Amendment Loans”). The Eighth Amendment Loans are to be repaid prior to all other loans previously made under the Credit Agreement and will mature on the earlier of April 10, 2025 and the occurrence of certain liquidity events. The Eighth Amendment Loans will bear interest at a per annum rate equal to Term SOFR plus 13.00% and a fee of 6.50% per annum will accrue on the unused portion of the commitments, which interest and fee will each be payable by capitalizing and adding such amount to the outstanding balance of the Eighth Amendment Loans. The Lenders received an upfront fee of 3% of the total amount of commitments upon entry into the Eighth Amendment, which fee was capitalized and added to the outstanding balance of the Eighth Amendment Loans, and will earn an additional fee upon repayment or other satisfaction of the Eighth Amendment Loans such that the minimum total cash return to the Lenders on amounts funded will equal 130%. The Eighth Amendment requires that the Company continue to maintain a minimum amount of liquidity and operate within a maximum variance to budget and that the Company use the net cash proceeds of any account receivables attributable to the Medicare Shared Savings Program to prepay the loans outstanding under the Credit Agreement. The Eighth Amendment also extended the waiver of certain events of default under the Credit Agreement in the limited manner set forth therein through August 15, 2024, subject to an earlier termination of the waiver upon the occurrence of certain specified events.

(23)

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless the context otherwise requires, references in this section to “CareMax,” “we,” “us,” “our,” and the “Company” refer to CareMax, Inc. together with its consolidated subsidiaries. The following discussion and analysis summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity, capital resources and cash flows of our company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q (the “Report”).

Forward-Looking Statements

This Report contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements, which represent our belief or current expectations, plans or forecasts of future events based on assumptions and information currently available to our management, involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control. The words “anticipate,” “believe,” “continue,” “plan,” “expect,” “estimate,” “may,” “could,” “should,” “project,” “will,” or the negative or other variations thereof and similar words or phrases or comparable terminology may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Actual results could differ materially from those discussed in these forward-looking statements due to a variety of risks and uncertainties and other factors, including but not limited to those contained in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”), which was filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2024, under the caption “Risk Factors” and, the following:

•
our history of losses and our future profitability remains uncertain and our net losses, level of indebtedness and significant cash used in operating activities have raised substantial doubt regarding our ability to continue as a going concern;
•
the execution of our growth strategy may include divesting certain assets or businesses, which we may be unable to successfully execute and we may be unable to achieve the benefits we expect from any such divestitures;
•
we may be unable to successfully implement cost-saving measures or achieve expected benefits under our plans to optimize performance of the MSO network and our centers;
•
the impact of our existing or future indebtedness and any associated debt covenants on our business and growth prospects;
•
the possibility we file for a restructuring under Chapter 11 of the US Bankruptcy Code if we are unable to successfully implement our plans;
•
the possibility that our rights under certain existing agreements could be impaired as a result of bankruptcy proceedings brought by Steward Health Care System;
•
the impact of restrictions on our current and future operations contained in certain of our agreements;
•
risks relating to lease termination, lease expense escalators, lease extensions, special charges and our inability to comply with provisions of our lease agreements;
•
our ability to integrate acquired businesses, including Steward Value-Based Care, and realize the expected benefits of any such acquisitions;
•
the viability of our growth strategy, including organic growth, and growth by acquisitions, and our ability to realize expected results, as well as our ability to access the capital necessary for such growth;
•
our ability to manage our growth effectively, execute our business plan, maintain high levels of service and patient satisfaction and adequately address competitive challenges;
•
our ability to attract new patients;
•
the dependence of our revenue and operations on a limited number of key payors;
•
the risk of termination, non-renewal or renegotiation of the MA contracts held by the health plans with which we contract, or the termination, non-renewal or renegotiation of our contracts with those plans;

(24)

•
the impact on our business from changes in the payor mix of our patients and potential decreases in our reimbursement rates;
•
competition from primary care facilities and other healthcare services providers;
•
competition for physicians and nurses, and shortages of qualified personnel;
•
the impact on our business of reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program, including the MA program;
•
the impact of the COVID-19 pandemic or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on our business, financial condition and results of operation;
•
the impact on our business of state and federal efforts to reduce Medicaid spending;
•
a shift in payor mix to Medicaid payors as well as an increase in the number of Medicaid patients may result in a reduction in the average rate of reimbursement;
•
our assumption under most of our agreements with health plans of some or all of the risk that the cost of providing services will exceed our compensation;
•
risks associated with estimating the amount of revenues and refund liabilities that we recognize under our risk agreements with health plans;
•
the impact on our business of security breaches, loss of data, or other disruptions causing the compromise of sensitive information or preventing us from accessing critical information;
•
the impact on our business of disruptions in our disaster recovery systems or management continuity planning;
•
the potential adverse impact of legal proceedings and litigation;
•
the impact of reductions in the quality ratings of the health plans we serve;
•
our ability to maintain and enhance our reputation and brand recognition;
•
our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems;
•
our ability to obtain, maintain and enforce intellectual property protection for our technology;
•
the potential adverse impact of claims by third parties that we are infringing on or otherwise violating their intellectual property rights;
•
our ability to protect the confidentiality of our trade secrets, know-how and other internally developed information;
•
the impact of any restrictions on our use of or ability to license data or our failure to license data and integrate third-party technologies;
•
our ability to protect data, including personal health data, and maintain our information technology systems from cybersecurity breaches and data leakage;
•
our ability to adhere to all of the complex government laws and regulations that apply to our business;
•
the impact on our business if we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting U.S. healthcare reform;
•
our ability to navigate rules and regulations that govern our licensing and certification, as well as credentialing processes with private payors, before we can receive reimbursement for their services;
•
insolvency, credit problems or other financial difficulties that could confront our counterparties in strategic acquisitions, investments and other collaborations could expose us to significant financial risk and significantly impact our ability to expand our overall profitability;
•
our reliance on strategic relationships with third-parties to implement our growth strategy;
•
that our estimates of market opportunity and forecasts of market and revenue growth may prove to be inaccurate;
•
our operating results and stock price may be volatile;

(25)

•
our failure to comply with continued listing requirements of the Nasdaq Global Select Market;
•
risks associated with estimating the amount of revenues that we recognize under our risk agreements with health plans;
•
our ability to develop and maintain proper and effective internal control over financial reporting; and
•
the impact of any prior period developments.

Due to the uncertain nature of these factors, management cannot assess the impact of each factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Any forward-looking statement speaks only as of the date on which statement is made, and we undertake no obligation to update any of these statements or circumstances occurring after the date of this Report. New factors may emerge, and it is not possible to predict all factors that may affect our business and prospects.

Our Business

As of June 30, 2024, CareMax operated 50 centers in Florida, New York, and Tennessee. CareMax offers a comprehensive range of medical services, including primary and preventative care, specialist services, diagnostic testing, chronic disease management and dental and optometry services under global capitation contracts.

CareMax’s comprehensive, high touch approach to health care delivery is powered by its CareOptimize technology platform. CareOptimize is a purpose-built end-to-end technology platform that aggregates data and analyzes that data using proprietary algorithms and machine learning to support more informed care delivery decisions and to focus care decisions on preventative chronic disease management and the social determinants of health. CareMax believes that CareOptimize is designed to drive better outcomes and lower costs. CareMax has shifted from selling the CareOptimize platform to new outside customers for a software subscription fee and is instead focused on providing the software to affiliated practices of its managed services organization (“MSO”) to further improve financial, clinical and quality outcomes from the affiliated providers.

CareMax’s centers offer 24/7 access to care through employed providers and provide a comprehensive suite of high-touch health care and social services to its patients, including primary care, specialty care, telemedicine, health & wellness, optometry, dental, pharmacy and transportation. CareMax’s differentiated healthcare delivery model is focused on care coordination with vertically integrated ambulatory care and community-centric services. The goal of CareMax is to intercede as early as possible to manage chronic conditions for its patient members in a proactive, holistic, and tailored manner to provide a positive influence on patient outcomes and a reduction in overall healthcare costs. CareMax focuses on providing access to high quality care in underserved communities.

While CareMax’s primary focus is providing care to Medicare eligible seniors who are mostly 65+ (approximately 83% and 78% of revenue for the six months ended June 30, 2024 and 2023, respectively, came from these patients), we also provide services to children and adults through Medicaid programs as well as through commercial insurance plans. Substantially all of the Medicare patients cared for in CareMax’s centers are enrolled in MA plans which are run by private insurance companies and are approved by and under contract with Medicare. With MA, patients get all of the same coverage as original Medicare, including emergency care, and most plans also include prescription drug coverage. In many cases, MA plans offer more benefits than original Medicare, including dental, vision, hearing and wellness programs. We contract with nearly all national and most regional, local Medicare Advantage plans.

In addition to Medicare Advantage contracts, through our MSO we service other Medicare patients through a variety of value-based contracts, such as Medicare Shared Savings Program (“MSSP”) and ACO REACH.

Reverse Stock Split

On January 31, 2024 (the “Effective Date”), the Company effected a 1-for-30 reverse stock split (the “Reverse Split”) of the Company’s Class A common stock, par value $0.0001 per share (“Class A Common Stock”). As a result of the Reverse Split, every thirty shares of the Class A Common Stock issued and outstanding as of the Effective Date automatically converted into one share of Class A Common Stock. No fractional shares were issued in connection with the Reverse Split. In lieu of issuing fractional shares, stockholders of record who otherwise would have been entitled to receive fractional shares were entitled to

(26)

rounding up of the fractional share to the nearest whole number. The Reverse Split automatically and proportionately adjusted, based on a 1-for-30 split ratio, all issued and outstanding shares of the Company’s common stock, as well as the terms of warrants outstanding at the time of the effectiveness of the Reverse Split. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of common stock. There was no change in the par value of our common stock or preferred stock.

References to number of shares of Class A Common Stock and per share data (except par value) in the accompanying financial statements and notes thereto for all periods presented have been adjusted to reflect the Reverse Split.

Steward Health Care Restructuring

On May 6, 2024, Steward Health Care System and certain of its affiliates commenced an in-court restructuring process through the filing of voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas. As previously disclosed, the Company entered into certain agreements with affiliates of Steward Health Care System in connection with the Steward Acquisition. In June 2024, as part of these bankruptcy proceedings, Steward Health Care System moved to reject certain of such contracts. Refer to Note 1, Description of Business and Going Concern, in our condensed consolidated financial statements included in this Report for further information.

Long-lived Asset Impairments

The Company reviews recoverability of its long-lived assets, including other intangible assets, property and equipment, and right-of-use assets, whenever facts and circumstances indicate that the carrying amount may not be fully recoverable. During the three months ended June 30, 2024, the Company performed an impairment assessment of its asset groups. The impairment assessment was triggered by the rejection by Steward Health Care System of certain contracts, as further explained in Steward Health Care Restructuring above. The impairment assessment was also triggered by the Company’s abandonment of a number of leased properties during the three months ended June 30, 2024 and a decision to cease use of additional leased properties following June 30, 2024.

Based on the results of these events and the impairment assessments, the Company recognized impairments of long-lived assets of $133.0 million, consisting of:

•
Property and equipment impairments and finance right-of-use asset abandonments of $25.2 million (Refer to Note 6, Property and Equipment, in our condensed consolidated financial statements included in this Report for further information);
•
Operating right-of-use asset abandonments of $59.0 million (Refer to Note 12, Leases, in our condensed consolidated financial statements included in this Report for further information); and
•
Other intangible asset impairments of $48.8 million (Refer to Note 5, Goodwill and Other Intangible Assets, in our condensed consolidated financial statements included in this Report for further information).

Key Factors Affecting Our Performance

Our Patients

As discussed above, the Company partners with Medicare, Medicaid, and commercial insurance plans. While CareMax currently services mostly Medicare patients, we also accept Medicare fee-for-service patients.

Patient Count as of* | Jun 30, 2022 |  | Sep 30, 2022 |  | Dec 31, 2022 |  | Mar 31, 2023 |  | Jun 30, 2023 |  | Sep 30, 2023 |  | Dec 31, 2023 |  | Mar 31, 2024 |  | Jun 30, 2024 |
Medicare Advantage |  | 37,000 |  |  | 39,500 |  |  | 93,500 |  |  | 95,500 |  |  | 102,500 |  |  | 107,000 |  |  | 111,500 |  |  | 107,000 |  |  | 104,000 |
Medicare Government VBC |  | — |  |  | — |  |  | 109,500 |  |  | 107,000 |  |  | 101,000 |  |  | 99,500 |  |  | 97,500 |  |  | 95,000 |  |  | 94,000 |
Medicaid |  | 29,500 |  |  | 31,500 |  |  | 33,500 |  |  | 33,500 |  |  | 30,500 |  |  | 28,500 |  |  | 25,500 |  |  | 31,000 |  |  | 22,000 |
Commercial |  | 21,500 |  |  | 22,000 |  |  | 22,000 |  |  | 34,500 |  |  | 38,500 |  |  | 38,000 |  |  | 36,000 |  |  | 17,000 |  |  | 16,500 |
Total Count |  | 88,000 |  |  | 93,000 |  |  | 258,500 |  |  | 271,000 |  |  | 272,500 |  |  | 273,000 |  |  | 270,000 |  |  | 250,000 |  |  | 236,500 |

* Figures may not sum due to rounding

Because CareMax accepts multiple insurance types, it uses a Medicare-Equivalent Member (“MCREM”) value in reviewing key factors of its performance. To determine the Medicare-Equivalent, CareMax estimates the amount of support typically

(27)

received by one Medicare patient as equivalent to the level of support received by three Medicaid or Commercial patients. This is due to Medicare patients on average having significantly higher levels of chronic and acute conditions that need higher levels of care. Due to this dynamic, a 3:1 ratio is applied to make year over year comparisons of total membership more comparable. The breakdown of membership for MCREM is below:

MCREM Count as of* | Jun 30, 2022 |  | Sep 30, 2022 |  | Dec 31, 2022 |  | Mar 31, 2023 |  | Jun 30, 2023 |  | Sep 30, 2023 |  | Dec 31, 2023 |  | Mar 31, 2024 |  | Jun 30, 2024 |
Medicare Advantage |  | 37,000 |  |  | 39,500 |  |  | 93,500 |  |  | 95,500 |  |  | 102,500 |  |  | 107,000 |  |  | 111,500 |  |  | 107,000 |  |  | 104,000 |
Medicare Government VBC |  | — |  |  | — |  |  | 109,500 |  |  | 107,000 |  |  | 101,000 |  |  | 99,500 |  |  | 97,500 |  |  | 95,000 |  |  | 94,000 |
Medicaid |  | 9,900 |  |  | 10,600 |  |  | 11,100 |  |  | 11,200 |  |  | 10,100 |  |  | 9,500 |  |  | 8,400 |  |  | 10,300 |  |  | 7,400 |
Commercial |  | 7,100 |  |  | 7,300 |  |  | 7,400 |  |  | 11,400 |  |  | 12,900 |  |  | 12,700 |  |  | 11,900 |  |  | 5,700 |  |  | 5,500 |
Total Count |  | 54,000 |  |  | 57,400 |  |  | 221,500 |  |  | 225,100 |  |  | 226,500 |  |  | 228,700 |  |  | 229,300 |  |  | 218,000 |  |  | 210,900 |

* Figures may not sum due to rounding

Medicare Advantage Patients

As of June 30, 2024, CareMax had approximately 104,000 MA patients of which 99% were in value-based agreements. Approximately 37% of patients in the Medicare Advantage value-based care agreements were in full-risk contracts. This means CareMax has been selected as the patient’s primary care provider and is financially responsible for some or all of the patient’s medical costs. CareMax is attributed an agreed percentage of the premium the Medicare plan receives from the Centers for Medicare and Medicaid Services (“CMS”) (typically a substantial majority of such premium given the risk assumed by the Company). A reconciliation is performed periodically and if premiums exceed medical costs paid by the MA plan, CareMax receives payment from the Medicare plan. If medical costs paid by the Medicare plan exceed premiums, CareMax is responsible to reimburse the Medicare plan.

Medicare Government Value-Based Care (“VBC”) Programs

As of June 30, 2024, CareMax had approximately 94,000 patients enrolled in Medicare Government VBC Programs, of which approximately 92% were in the MSSP and 8% were in the ACO REACH program. The MSSP is sponsored by the CMS. The MSSP allows participating Accountable Care Organizations (“ACOs”) to receive a share of cost savings they generate in connection with the management of costs and quality of medical services rendered to Medicare beneficiaries. Payments to the ACO participants, if any, are calculated annually and paid once a year by CMS on cost savings generated by the ACO participant relative to the ACO participants’ CMS benchmark. Under the MSSP, the ACO must meet certain qualifications to receive the full amount of its allocable cost savings or they either receive nothing or are responsible for shared losses. The MSSP rules require CMS to develop a benchmark for savings to be achieved by each participant if the participant is to receive shared savings. An ACO that meets the MSSP’s quality performance standards will be eligible to receive a share of the savings to the extent its assigned beneficiary medical expenditures are below the medical expenditure benchmark provided by CMS. A Minimum Savings Rate (“MSR”), which varies depending on the number of beneficiaries assigned to the ACO, must be achieved before the ACO can receive up to a 75% share of the savings if quality performance standards are met; the ACO is also responsible for 40% of the deficit. Once the MSR is surpassed, all the savings below the benchmark provided by CMS will be shared with the ACO.

Medicaid Patients

As of June 30, 2024, CareMax had approximately 22,000 Medicaid patients of which 100% were in value-based agreements. Approximately 91% of patients in the Medicaid value-based care agreements were in full-risk contracts. Using the MCREM metric, the level of support required to manage these Medicaid patients equates to that of approximately 7,400 Medicare patients. In Florida, most Medicaid recipients are enrolled in the Statewide Medicaid Managed Care program.

Similar to the risk it takes with Medicare, CareMax is attributed an agreed percentage of the premium the Medicaid plan receives from Florida’s Agency for Health Care Administration (“AHCA”) (typically a substantial majority of such premium given the risk assumed by the Company). A reconciliation is performed periodically and if premiums exceed medical costs paid by the Medicaid plan, CareMax receives payment from the Medicaid plan. If medical costs paid by the Medicaid plan exceed premiums, we are responsible to reimburse the Medicaid plan.

(28)

Commercial Patients

As of June 30, 2024, CareMax managed approximately 16,500 commercial patients of which 100% were under a value-based agreement that provided upside-only financial incentives for quality and utilization performance. Using the MCREM metric, the level of support required to manage these commercial patients equates to that of approximately 5,500 Medicare patients.

CareMax cares for a number of commercial patients (less than 1% of the Company's total patients) for whom it is reimbursed on a fee-for-service basis via their health plan in situations where it does not have a capitation relationship with that particular health plan.

CareMax fee for-service revenue, received directly from commercial plans, on a per patient basis is typically lower than its per patient revenue for at-risk patients based in part because its fee-for-service revenue covers only the primary care services that it directly provides to the patient, while the risk revenue is intended to compensate it for the services directly performed by CareMax as well as the financial risk that it assumes related to the third-party medical expenses of at-risk patients.

Contracts with Payors

Our economic model relies on its capitated partnerships with payors which manage and market Medicare plans across the United States. CareMax has established strategic value-based relationships with a number of different payors for Medicare Advantage patients, Medicaid patients, and ACA patients. During the six months ended June 30, 2024, our three largest payor relationships were Payor A, Payor C, and Payor B, which generated 20%, 19%, and 14%, of our revenue, respectively. During the six months ended June 30, 2023, our three largest payor relationships were Payor A, Payor C and Payor E, which generated 26%, 22% and 16% of our revenue, respectively. These existing contracts and relationships with our national partners and their understanding of the value of the CareMax model reduces the risk of entering into new markets as CareMax typically seeks to have payor contracts in place before entering a new market. Maintaining, supporting, and growing these relationships, particularly as CareMax enters new markets, are critical to our long-term success. We believe CareMax’s model is well-aligned with that of its payor partners - to drive better health outcomes for their patients, enhance patient satisfaction, and drive incremental patient and revenue growth. This alignment of interests helps ensure our continued success with our payor partners.

Effectively Manage the Cost of Care for Our Patients

The capitated nature of our contracting with payors requires us to prudently manage the medical expense of our patients. Our external provider costs are our largest expense category, representing 55% of our total operating expenses for the six months ended June 30, 2024 and 53% of our total operating expenses for the six months ended June 30, 2023. Our care model focuses on leveraging the primary care setting as a means of avoiding costly downstream healthcare costs, such as acute hospital admissions. Our patients retain the freedom to seek care at emergency rooms or hospitals; we do not restrict their access to care. Therefore, we could be liable for potentially large medical claims should we not effectively manage our patients’ health. We utilize stop-loss insurance for our patients, protecting us from medical claims in excess of certain levels.

Seasonality to our Business

Due to the large number of dual-eligible patients (meaning eligible for both Medicare and Medicaid) we serve, the annual enrollment period does not materially affect our growth during the year. We typically see large increases in ACA patients during the first quarter as a result of the ACA annual enrollment period (October to December). However, this is not a large portion of our business.

Our operational and financial results will experience some variability depending upon the time of year in which they are measured. This variability is most notable in the following areas:

Per-Patient Revenue

The revenue derived from our at-risk patients is a function of the percentage of premium we have negotiated with our payor partners, as well as our ability to accurately and appropriately document the acuity of a patient. We experience some seasonality with respect to our per-patient revenue, as it will generally decline over the course of the year. In January of each year, CMS revises the risk adjustment factor for each patient based upon health conditions documented in the prior year, leading to changes in per-patient revenue. As the year progresses, our per-patient revenue declines as new patients join us, typically with less

(29)

complete or accurate documentation (and therefore lower risk-adjustment scores), and patient mortality disproportionately impacts our higher-risk (and therefore greater revenue) patients.

External Provider Costs

External Provider Costs will vary seasonally depending on a number of factors, but most significantly the weather. Certain illnesses, such as the influenza virus, are far more prevalent during colder months of the year, which can result in an increase in medical expenses during these time periods. We would therefore expect to see higher levels of per-patient medical costs in the first and fourth quarters. Medical costs also depend upon the number of business days in a period. Shorter periods will have lesser medical costs due to fewer business days. Business days can also create year-over-year comparability issues if one year has a different number of business days compared to another. We would also expect to experience an impact in the future should there be another pandemic such as COVID-19, which may result in increased or decreased total medical costs depending upon the severity of the infection, the duration of the infection and the impact to the supply and availability of healthcare services for our patients.

Payor Settlements

As it relates to our MSSP contracts, settlements from the prior year from the CMS typically take place during the fourth quarter of each year, which results in variability of our accounts receivable, cash flow from operations, and cash balances throughout the year.

Investments in Centers

We have invested into de novo centers both within and outside of Florida. De novo centers require upfront capital and operating expenditures, which typically are not fully offset by revenues in the near-term, as a result of which we expect a period of unprofitability in our de novo centers before they break even. Costs we incur prior to opening of a de novo center include (1) incremental payroll costs from employees specifically associated with the operational, contractual, physical, or regulatory infrastructure for de novo centers, prior to their opening; (2) legal costs directly associated with the de novo centers, incurred prior to their opening, which includes services such as execution of leases, health plan contracts and other agreements; (3) other expenses related to diligence, design, permitting, and other “soft costs” at new sites; and (4) rent and facility expenses prior to center opening. Once a de novo center opens, we incur post-opening losses, which consist of center-level operating losses recognized at a de novo center until the center breaks even. The de novo post-opening losses consist of revenue, external provider costs and cost of care allocated to the de novo center. During the six months ended June 30, 2024 and 2023, we incurred de novo pre-opening costs and post-opening losses, on a combined basis, of $9.4 million and $11.6 million, respectively.

Key Business Metrics

In addition to our financial information which conforms with generally accepted accounting principles in the United States of America (“GAAP”), management reviews a number of operating and financial metrics, including the following key metrics, to evaluate its business, measure its performance, identify trends affecting its business, formulate business plans, and make strategic decisions.

Use of Non-GAAP Financial Information

Certain financial information and data contained in this Report is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any periodic filing, information or proxy statement, or prospectus or registration statement to be filed by the Company with the SEC. Some of the financial information and data contained in this Report, such as Adjusted EBITDA and Platform Contribution have not been prepared in accordance with GAAP. These non-GAAP measures of financial results are not GAAP measures of our financial results or liquidity and should not be considered as an alternative to net income (loss) as a measure of financial results, cash flows from operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. The Company believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. Management uses these non-GAAP measures for trend analyses and for budgeting and planning purposes.

(30)

The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing the Company’s financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which expense and income are excluded or included in determining these non-GAAP financial measures. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. You should review the Company’s GAAP financial statements, which are included in this Report.

Adjusted EBITDA

Beginning with the Company’s Form 10-Q for the three months ended June 30, 2023, for all periods presented, the Company updated its calculation of the reconciliation of Adjusted EBITDA on a retrospective basis to no longer add back certain compensation costs for stay-on bonuses and duplicative salaries previously included within the Business Combination integration costs adjustment.

Adjusted EBITDA is defined as net income or loss before interest expense, depreciation and amortization, impairment of long-lived assets, remeasurement of derivative and contingent earnout liabilities, goodwill impairment, stock-based compensation, Business Combination integration costs, acquisition and disposition related costs, income tax expense, and other income or expenses that are considered one-time in nature as determined by management.

Adjusted EBITDA is intended to be used as a supplemental measure of our performance that is neither required by, nor presented in accordance with GAAP. Management believes that the use of Adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing its financial measure with those of comparable companies, which may present similar non-GAAP financial measures to investors. However, we may incur future expenses similar to those excluded when calculating these measures. In addition, our presentations of these measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our computation of Adjusted EBITDA may not be comparable to other similarly titled measures computed by other companies, because all companies may not calculate Adjusted EBITDA in the same fashion. Due to these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP.

Reconciliation to Adjusted EBITDA

|  | Three Months Ended June 30, |  |  |  |  |  | Six Months Ended June 30, |  |  |  |
(in thousands) |  | 2024 |  |  | 2023 |  |  | Y/Y Change |  |  | 2024 |  |  | 2023 |  |  | Y/Y Change |
Net loss |  | $ | (170,558 | ) |  | $ | (32,376 | ) |  | $ | (138,181 | ) |  | $ | (213,966 | ) |  | $ | (114,458 | ) |  | $ | (99,507 | )
Interest expense |  |  | 20,376 |  |  |  | 13,197 |  |  |  | 7,179 |  |  |  | 40,131 |  |  |  | 23,908 |  |  |  | 16,224 |
Depreciation and amortization |  |  | 6,512 |  |  |  | 6,828 |  |  |  | (315 | ) |  |  | 13,218 |  |  |  | 13,404 |  |  |  | (187 | )
Impairment of long-lived assets |  |  | 132,990 |  |  |  | — |  |  |  | 132,990 |  |  |  | 132,990 |  |  |  | — |  |  |  | 132,990 |
Remeasurement of derivative and contingent earnout liabilities |  |  | (2,355 | ) |  |  | 15,786 |  |  |  | (18,141 | ) |  |  | 26 |  |  |  | (21,456 | ) |  |  | 21,482 |
Goodwill impairment |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 98,000 |  |  |  | (98,000 | )
Stock-based compensation |  |  | 2,396 |  |  |  | 2,464 |  |  |  | (68 | ) |  |  | 4,761 |  |  |  | 4,762 |  |  |  | (1 | )
Business Combination integration costs (1) |  |  | 399 |  |  |  | 686 |  |  |  | (287 | ) |  |  | 780 |  |  |  | 1,402 |  |  |  | (622 | )
Acquisition and disposition related costs (2) |  |  | (669 | ) |  |  | 815 |  |  |  | (1,484 | ) |  |  | 383 |  |  |  | 1,436 |  |  |  | (1,053 | )
Other (3) |  |  | (421 | ) |  |  | (535 | ) |  |  | 114 |  |  |  | (312 | ) |  |  | (722 | ) |  |  | 410 |
Income tax expense |  |  | 177 |  |  |  | 177 |  |  |  | — |  |  |  | 354 |  |  |  | 355 |  |  |  | (1 | )
Adjusted EBITDA |  | $ | (11,152 | ) |  | $ | 7,042 |  |  | $ | (18,194 | ) |  | $ | (21,634 | ) |  | $ | 6,630 |  |  | $ | (28,265 | )

(1)
Represents initial costs to set up public company processes, incremental vendor expenses identified as temporary or duplicative and expected to be rationalized in the short term, and legal and professional expenses outside of the ordinary course of business, which are being incurred as part of the Company’s efforts as it integrates the two privately held companies that were combined in the Business Combination. Significant components of Business Combination integration costs were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30, |
(in thousands) | 2024 |  | 2023 |  | 2024 |  | 2023 |
Consulting and legal fees (a) | $ | 389 |  | $ | 237 |  | $ | 760 |  | $ | 519 |
Other (b) |  | 10 |  |  | 449 |  |  | 20 |  |  | 883 |
| $ | 399 |  | $ | 686 |  | $ | 780 |  | $ | 1,402 |

(31)

(a) Represents consulting and legal costs directly associated with efforts related to integration of the two privately held companies that were combined in the Business Combination.

(b) Represents primarily vendor expenses identified as temporary or duplicative and/or expenses outside the ordinary course of business and not necessary to run the Company’s business.

(2)
Represents legal and incremental compensation payroll costs directly associated with efforts to achieve synergies related to closed transactions and legal and advisory costs related to exploration of potential dispositions. Significant components of the acquisition and disposition related costs were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30, |
(in thousands) | 2024 |  | 2023 |  | 2024 |  | 2023 |
Advisor and other professional fees (a) | $ | (1,112 | ) | $ | (34 | ) | $ | (588 | ) | $ | (292 | )
Compensation costs (b) |  | 444 |  |  | 849 |  |  | 972 |  |  | 1,728 |
| $ | (669 | ) | $ | 815 |  | $ | 383 |  | $ | 1,436 |

(a) Includes payments to our third-party transaction advisory firm associated with transaction contracts, including the Steward transaction that closed in November 2022. Also, costs include legal and accounting fees directly associated with contemplated or closed transactions or potential dispositions.

(b) Includes incremental payroll compensation expense for employees directly associated with services to achieve synergies related to closed transactions.

(3)
Components of other were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30, |
(in thousands) | 2024 |  | 2023 |  | 2024 |  | 2023 |
Interest income | $ | (277 | ) | $ | (602 | ) | $ | (945 | ) | $ | (855 | )
Severance costs |  | — |  |  | — |  |  | 694 |  |  | — |
Other |  | (144 | ) |  | 67 |  |  | (61 | ) |  | 133 |
| $ | (421 | ) | $ | (535 | ) | $ | (312 | ) | $ | (722 | )

Operating Metrics and Non-GAAP Platform Contribution

In addition to our GAAP financial information, we review a number of operating and financial metrics, including the following key metrics, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions.

The following metrics are as of the end of the indicated date, except for Platform Contribution, which is for the three month period ended as of the indicated date:

Non-GAAP Operating Metrics | Jun 30, 2022 |  | Sep 30, 2022 |  | Dec 31, 2022 |  | Mar 31, 2023 |  | Jun 30, 2023 |  | Sep 30, 2023 |  | Dec 31, 2023 |  | Mar 31, 2024 |  | Jun 30, 2024 |
Centers |  | 48 |  |  | 51 |  |  | 62 |  |  | 62 |  |  | 62 |  |  | 62 |  |  | 56 |  |  | 55 |  |  | 50 |
Markets |  | 6 |  |  | 7 |  |  | 7 |  |  | 7 |  |  | 7 |  |  | 7 |  |  | 7 |  |  | 6 |  |  | 6 |
Patients (MCREM)* |  | 54,000 |  |  | 57,400 |  |  | 221,500 |  |  | 225,100 |  |  | 226,500 |  |  | 228,700 |  |  | 229,300 |  |  | 218,000 |  |  | 210,900 |
Patients in value-based care arrangements (MCREM) |  | 81.0 | % |  | 78.2 | % |  | 97.6 | % |  | 99.0 | % |  | 99.4 | % |  | 98.8 | % |  | 98.8 | % |  | 99.1 | % |  | 99.4 | %
Platform Contribution ($, millions) | $ | 21.6 |  | $ | 20.6 |  | $ | 25.6 |  | $ | 24.7 |  | $ | 28.6 |  | $ | 21.1 |  | $ | (55.6 | ) | $ | 9.1 |  | $ | 3.7 |
* MCREM defined as Medicare Equivalent Members, which assumes the level of support received by a Medicare patient is equivalent to that received by three Medicaid or Commercial patients. |

Centers

We define our centers as those primary care centers open for business and open for enrollment of patients at the end of a particular period.

Patients (MCREM)

MCREM patients include both at-risk MA patients (those patients for whom we are financially responsible for their total healthcare costs) as well as risk and non-risk, non-MA patients. We define our total at-risk patients as patients who have selected us as their provider of primary care medical services as of the end of a particular period and for whom we take responsibility for at least some degree of downside risk in capitated contracts. An at-risk patient remains active in our system until we are informed by the health plan the patient is no longer active. As discussed above, CareMax calculates the amount of support

(32)

typically received by one Medicare patient as equivalent to the level of support received by three Medicaid or Commercial patients.

Platform Contribution

We define Platform Contribution as gross profit plus depreciation and amortization, stock-based compensation recognized within cost of care and other adjustments, as disclosed below. Gross profit is defined as revenue less the sum of (i) external provider costs; (ii) cost of care, including stock-based compensation, and (iii) depreciation and amortization expense. We believe this metric best reflects the economics of our care model as it includes all medical claims expense associated with our patients’ care as well as the costs we incur to care for our patients at our centers. As a center matures, we expect the Platform Contribution from that center to increase both in terms of absolute dollars as well as a percentage of revenue. This increase will be driven by improving patient contribution economics over time, as well as our ability to generate operating leverage on the costs of our centers. Our aggregate Platform Contribution may not increase despite improving economics at our existing centers should we open new centers at a pace that skews our mix of centers towards newer centers.

The following table provides a reconciliation of gross profit, the most closely comparable GAAP financial measure, to Platform Contribution:

| Three Months Ended |
(in millions) | Jun 30, 2022 |  | Sep 30, 2022 |  | Dec 31, 2022 |  | Mar 31, 2023 |  | Jun 30, 2023 |  | Sep 30, 2023 |  | Dec 31, 2023 |  | Mar 31, 2024 |  | Jun 30, 2024 |
Gross profit (a) | $ | 15.4 |  | $ | 14.8 |  | $ | 17.2 |  | $ | 17.1 |  | $ | 20.4 |  | $ | 12.0 |  | $ | (63.5 | ) | $ | 1.5 |  | $ | (3.6 | )
Depreciation and amortization |  | 4.9 |  |  | 4.6 |  |  | 7.2 |  |  | 6.6 |  |  | 6.8 |  |  | 6.8 |  |  | 7.6 |  |  | 6.7 |  |  | 6.5 |
Stock-based compensation |  | 1.3 |  |  | 1.2 |  |  | 1.2 |  |  | 1.0 |  |  | 1.3 |  |  | 1.2 |  |  | 0.1 |  |  | 0.7 |  |  | 0.7 |
Other adjustments (b) |  | 0.1 |  |  | 0.1 |  |  | — |  |  | — |  |  | — |  |  | 1.0 |  |  | 0.2 |  |  | 0.2 |  |  | 0.1 |
Platform Contribution | $ | 21.6 |  | $ | 20.6 |  | $ | 25.6 |  | $ | 24.7 |  | $ | 28.6 |  | $ | 21.1 |  | $ | (55.6 | ) | $ | 9.1 |  | $ | 3.7 |
(a) Gross profit reflects the reclassification of stock-based compensation expense previously included in corporate, general and administrative expenses, which decreased gross profit by $1.3 million during the three months ended June 30, 2022, $1.2 million during the three months ended September 30, 2022, and $1.2 million during the three months ended December 31, 2022. |
(b) Other adjustments include incremental costs related to post-Business Combination integration initiatives and other one-time center-level costs. During the three months ended September 30, 2023, December 31, 2023, and March 31, 2024, other adjustments include $1.0 million, $0.2 million and $0.2 million, respectively, of severance costs related to center staff. |

Components of Results of Operations

Revenue

Medicare Risk-Based Revenue and Medicaid Risk-Based Revenue. Our Medicare and Medicaid risk-based revenue consists primarily of capitation fees for medical services provided by us or managed by our MSO under a global capitation arrangement made directly with various MA payors. Capitation is a fixed amount of money per patient per month paid in advance for the delivery of health care services, whereby we are generally liable for medical costs in excess of the fixed payment and are able to retain any surplus created if medical costs are less than the fixed payment. A portion of our capitated revenues are typically prepaid monthly to us based on the number of MA patients selecting us as their primary care provider. Our capitated rates are determined as a percentage of the premium the MA plan receives from CMS for our at-risk members. Those premiums are determined via a competitive bidding process with CMS and are based upon the cost of care in a local market and the average utilization of services by the patients enrolled. Medicare pays capitation using a “risk adjustment model,” which compensates providers based on the health status (acuity) of each individual patient. Payors with higher acuity patients receive more in premium, and those with lower acuity patients receive less in premium. Under the risk adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after the final data is compiled. As premiums are adjusted via this risk adjustment model, our capitation payments will correlate with how our payor partners’ premiums change with CMS. Risk adjustment in future periods may be impacted by COVID-19 and our inability to accurately document the health needs of our patients, which may have an adverse impact on our revenue.

For Medicaid, premiums are determined by Florida’s AHCA and base rates are adjusted annually using historical utilization data projected forward by a third-party actuarial firm. The rates are established based on specific cohorts by age and sex and geographical location. AHCA uses a “zero sum” risk adjustment model that establishes acuity for certain cohorts of patients quarterly, and depending on the scoring of that acuity, may periodically shift premiums from health plans with lower acuity members to health plans with higher acuity members.

(33)

Government Value-Based Care Revenue. Government value-based care revenue consists primarily of revenue derived from the MSSP. The MSSP is sponsored by the CMS. The MSSP allows ACOs to receive a share in cost savings they generate in connection with the managing of costs and quality of medical services rendered to Medicare beneficiaries. Payments to ACO participants, if any, are calculated annually and paid once a year by CMS on cost savings generated by the ACO participant relative to the ACO participants’ CMS benchmark. Under the MSSP, an ACO must meet certain qualifications to receive the full amount of its allocable cost savings or they either receive nothing or are responsible for shared losses. The MSSP rules require CMS to develop a benchmark for savings to be achieved by each ACO if the ACO is to receive shared savings. An ACO that meets the MSSP’s quality performance standards will be eligible to receive a share of the savings to the extent its assigned beneficiary medical expenditures are below the medical expenditure benchmark provided by CMS. A Minimum Savings Rate (“MSR”) must be achieved before the ACO can receive a share of the savings. Once the MSR is surpassed, all the savings below the benchmark provided by CMS will be shared at a certain percentage with the ACO. The MSR varies depending on the number of beneficiaries assigned to the ACO.

Other Revenue. Other revenue consists primarily of professional capitation payments and pharmacy revenue. These revenues are a fixed amount of money per patient per month paid in advance for the delivery of primary care services only, whereby CareMax is not liable for medical costs in excess of the fixed payment. Capitated revenues are typically paid monthly to CareMax based on the number of patients selecting us as their primary care provider. Our capitated rates are fixed, contractual rates. Incentive payments for Healthcare Effectiveness Data and Information Set (“HEDIS”) and any services paid on a fee-for-service basis by a health plan are also included in other revenue. Other revenue also includes ancillary fees earned under contracts with certain payors for the provision of certain care coordination and other care management services. These services are provided to patients covered by these payors regardless of whether those patients receive their care from our affiliated medical groups. Revenue for primary care service for patients in partial risk or upside-only contracts, pharmacy revenue and revenue generated from CareOptimize are reported in other revenue.

Operating Expenses

External Provider Costs. External provider costs include services at-risk patients utilize that are rendered by providers other than CareMax. These include claims paid by the health plan and estimates for unpaid claims. The estimated reserve for incurred but not paid claims is included as a reduction to accounts receivable as we do not pay medical claims. Actual claims expense will differ from the estimated liability due to differences in estimated and actual patient utilization of health care services, the amount of charges, and other factors. We typically reconcile our medical claims expense with our payor partners on a monthly basis and adjust our estimate of incurred but not paid claims if necessary. To the extent we revise our estimates of incurred but not paid claims for prior periods up or down, there would be a correspondingly favorable or unfavorable effect on our current period results that may or may not reflect changes in long term trends in our performance. We expect our medical claims expenses to increase in both absolute dollar terms as well as on a PMPM basis given the healthcare spending trends within the Medicare population and the increasing disease burden of patients as they age.

The Company re-evaluated key assumptions and estimates and based on this analysis, the Company identified changes in estimates to revenue, external provider costs, short-term and long-term accounts receivable, net, and risk settlement liabilities. Accordingly, the Company recognized the following changes in prior year estimates in each respective period (in thousands):

| Six Months Ended June 30, |
Increase (decrease) | 2024 |  |  | 2023 |
Revenue | $ | 8,475 |  |  | $ | (22,964 | )
External provider costs |  | (12,231 | ) |  |  | (1,736 | )
Short-term and long-term accounts receivable, net |  | (926 | ) |  |  | (21,228 | )
Risk settlement liabilities |  | (21,631 | ) |  |  | — |

For the six months ended June 30, 2024, the decreases were mostly driven by favorable development in provider costs from Medicare full risk plans, partially offset by unfavorable development in provider costs from Medicaid full risk plans primarily from 2022 dates of service. For the six months ended June 30, 2023, the developments related to the prior year dates of service were primarily driven by new, updated information regarding MSO membership at one health plan, an unseasonably early flu season, and more current data from one Medicaid health plan.

Cost of Care. Cost of care includes the costs of additional medical services we provide to patients that are not paid by the plan. These services include patient transportation, medical supplies, auto insurance and other specialty costs, like dental or vision. In some instances, we have negotiated better rates than the health plans for these health plan covered services. In addition, cost

(34)

of care includes rent, utilities and facilities costs required to maintain and operate our centers, and compensation of the clinic and support staff.

Cost of care also includes distributions to affiliate IPA physicians and physician groups. Expenses from our physician groups that contract with our MSO are consolidated with other clinical and MSO expenses to determine profitability for our at-risk and fee-for-service arrangements. Physician group economics are not evaluated on an individual provider basis, as MSO related medical expenses are consolidated at the contract level.

We measure the incremental cost of our capitation agreements by starting with our center-level expenses, which are calculated based upon actual expenses incurred at a specific center for a given period of time and expenses that are incurred centrally and allocated to centers on a ratable basis. These expenses are allocated to our at-risk patients based upon the number of visit slots these patients utilized compared to the total slots utilized by all of our patients. All visits, however, are not identical and do not require the same level of effort and expense on our part. Certain types of visits are more time and resource intensive and therefore result in higher expenses for services provided internally. Generally, patients who are earlier in their tenure with CareMax utilize a higher percentage of these more intensive visits, as we get to know the patient and properly assess and document such patient’s health condition.

Sales and Marketing Expenses. Sales and marketing expenses represent employee-related expenses, such as salaries, commissions and related benefits, including stock-based compensation for sales and marketing departments. These expenses also include marketing and community relations related costs, such as radio and television advertising, events and promotional items.

Corporate, General and Administrative Expenses. Corporate, general, and administrative expenses represent employee-related expenses, such as salaries and related benefits, including stock-based compensation for support functions like finance, legal, human resources, and business developments. In addition, these expenses include corporate technology, third party professional services and corporate occupancy costs.

Depreciation and Amortization Expenses. Depreciation and amortization expenses are primarily attributable to our capital investments and consist of fixed asset depreciation and amortization of intangibles considered to have definite lives.

Impairment of Long-Lived Assets. Impairment of long-lived assets includes impairments of intangible assets and property and equipment and ROU assets.

Nonoperating Income (Expenses)

Interest Expense. Interest expense consists primarily of interest payments, paid-in-kind interest, amortization of debt issuance costs and debt discount on our outstanding borrowings.

Change in Fair Value of Derivative Liabilities. Change in fair value of derivative liabilities consists of changes in fair value of the public w arrants and private placement warrants and Credit Agreement embedded derivatives.

Gain (Loss) on Remeasurement of Contingent Earnout Liabilities. Gain (loss) on remeasurement of contingent earnout liabilities consists of changes in the fair value of contingent earnout liabilities.

Other Income (Expenses), Net. Other income (expenses), net, consists of miscellaneous non-operating corporate expenses and income.

(35)

Results of Operations

Three Months Ended June 30, 2024 compared to Three Months Ended June 30, 2023

The following table sets forth our condensed consolidated statements of operations data for the periods indicated:

| Three Months Ended June 30, |
(in thousands) | 2024 |  | 2023 |  | $ Change |  | % Change |
Revenue |  |  |  |  |  |  |  |
Medicare risk-based revenue | $ | 154,857 |  | $ | 155,486 |  | $ | (629 | ) |  | (0.4 | %)
Medicaid risk-based revenue |  | 22,865 |  |  | 30,054 |  |  | (7,189 | ) |  | (23.9 | %)
Government value-based care revenue |  | 14,690 |  |  | 22,206 |  |  | (7,516 | ) |  | (33.8 | %)
Other revenue |  | 6,215 |  |  | 16,694 |  |  | (10,479 | ) |  | (62.8 | %)
Total revenue |  | 198,627 |  |  | 224,440 |  |  | (25,814 | ) |  | (11.5 | %)
Operating expenses |  |  |  |  |  |  |  |
External provider costs |  | 153,115 |  |  | 156,995 |  |  | (3,880 | ) |  | (2.5 | %)
Cost of care |  | 42,593 |  |  | 40,192 |  |  | 2,400 |  |  | 6.0 | %
Sales and marketing |  | 1,378 |  |  | 3,327 |  |  | (1,949 | ) |  | (58.6 | %)
Corporate, general and administrative |  | 14,780 |  |  | 20,849 |  |  | (6,069 | ) |  | (29.1 | %)
Depreciation and amortization |  | 6,512 |  |  | 6,828 |  |  | (315 | ) |  | (4.6 | %)
Impairment of long-lived assets |  | 132,990 |  |  | — |  |  | 132,990 |  |  | 100.0 | %
Total costs and expenses |  | 351,368 |  |  | 228,191 |  |  | 123,177 |  |  | 54.0 | %
Operating loss |  | (152,741 | ) |  | (3,750 | ) |  | (148,991 | ) |  | (3,972.6 | %)
Nonoperating (expenses) income |  |  |  |  |  |  |  |
Interest expense |  | (20,376 | ) |  | (13,197 | ) |  | (7,179 | ) |  | (54.4 | %)
Change in fair value of derivative liabilities |  | 2,355 |  |  | 434 |  |  | 1,921 |  |  | 442.8 | %
Loss on remeasurement of contingent earnout liabilities |  | — |  |  | (16,220 | ) |  | 16,220 |  |  | 100.0 | %
Other income, net |  | 382 |  |  | 534 |  |  | (153 | ) |  | (28.6 | %)
Total nonoperating expenses |  | (17,639 | ) |  | (28,449 | ) |  | 10,809 |  |  | 38.0 | %
Loss before income tax |  | (170,381 | ) |  | (32,199 | ) |  | (138,182 | ) |  | (429.1 | %)
Income tax expense |  | (177 | ) |  | (177 | ) |  | — |  |  | 0.0 | %
Net loss | $ | (170,558 | ) | $ | (32,376 | ) | $ | (138,182 | ) |  | (426.8 | %)

* Figures may not sum due to rounding

Medicare risk-based revenue. Medicare risk-based revenue was $154.9 million for the three months ended June 30, 2024, a decrease of $0.6 million, or 0.4%, compared to $155.5 million for the three months ended June 30, 2023. The slight decrease was driven primarily by a 10.6% increase in the total number of at-risk Medicare patients and a favorable net prior period development of approximately $9.0 million, offset by a 9.9% decrease in rates.

Medicaid risk-based revenue. Medicaid risk-based revenue was $22.9 million for the three months ended June 30, 2024, a decrease of $7.2 million, or 23.9%, compared to $30.1 million for the three months ended June 30, 2023. This decrease was driven primarily by a 27.1% decrease in the total number of at-risk Medicaid patients, partially offset by a 4.4% increase in rates.

Government value-based care revenue. Government value-based care revenue was $14.7 million for the three months ended June 30, 2024, a decrease of $7.5 million, or 33.8%, compared to $22.2 million for the three months ended June 30, 2023. The decrease is the result of lower estimated MSSP shared savings, as compared to prior year, as well as unfavorable prior period development from lowering estimates related to prior period accruals.

Other revenue. Other revenue was $6.2 million for the three months ended June 30, 2024, a decrease of $10.5 million, or 62.8%, compared to $16.7 million for the three months ended June 30, 2023. The decrease is primarily due to a decrease in partial risk revenue, as risk contracts are converted to full risk, and lower revenue from incentive-based programs.

External provider costs. External provider costs were $153.1 million for the three months ended June 30, 2024, a decrease of $3.9 million, or 2.5%, compared to $157.0 million for the three months ended June 30, 2023. The slight decrease was driven by a favorable net prior period development of approximately $4.9 million, partially offset by a decrease in claim costs and a 2.5% increase in the total number of at-risk patients.

Cost of care. Cost of care expenses were $42.6 million for the three months ended June 30, 2024, an increase of $2.4 million, or 6.0%, compared to $40.2 million for the three months ended June 30, 2023.

(36)

Sales and marketing expenses. Sales and marketing expenses were $1.4 million for the three months ended June 30, 2024, a decrease of $1.9 million, or 58.6%, compared to $3.3 million for the three months ended June 30, 2023. The decrease is due to a reduction in our sales staff and marketing efforts in 2024 as compared to 2023, related to our initiative to reduce operating expenses.

Corporate, general and administrative expenses. Corporate, general and administrative expenses were $14.8 million for the three months ended June 30, 2024, a decrease of $6.1 million, or 29.1%, compared to $20.8 million for the three months ended June 30, 2023. The increase is primarily due to lower payroll-related expenses related to our initiative to reduce operating expenses, partially offset by higher advisory and legal fees.

Depreciation and amortization expenses. Depreciation and amortization expenses were $6.5 million for the three months ended June 30, 2024, a decrease of $0.3 million, or 4.6%, compared to $6.8 million for the three months ended June 30, 2023.

Impairment of long-lived assets. Impairment of long-lived assets was $133.0 million for the three months ended June 30, 2024, which included impairment of intangible assets, ROU assets and property and equipment. Refer to Note 1, Description of Business and Going Concern, in our condensed consolidated financial statements included in this Report for further information.

Interest expense. Interest expense was $20.4 million for the three months ended June 30, 2024, an increase of $7.2 million, or 54.4%, compared to $13.2 million for the three months ended June 30, 2023. This increase was due to the increased borrowings and higher weighted-average interest rate. Refer to Note 7, Debt and Related Party Debt, in our condensed consolidated financial statements included in this Report for additional information on the borrowings outstanding as of June 30, 2024.

Change in fair value of derivative liabilities. The Company recorded a gain on fair value of derivative liabilities of $2.4 million for the three months ended June 30, 2024, an increase of $1.9 million, or 442.8%, compared to $0.4 million for the three months ended June 30, 2023. This increase was driven by the reduction in the fair value of the Credit Agreement embedded derivatives during the three months ended June 30, 2024.

Loss on remeasurement of contingent earnout liabilities. We recorded a loss on remeasurement of contingent earnout liabilities related to Steward Acquisition of $16.2 million for the three months ended June 30, 2023, driven by the increase in the market value of the Company’s Class A Common Stock from March 31, 2023 to June 30, 2023. There was no activity during the three months ended June 30, 2024 due to the contingent earnout consideration being reclassified into additional paid-in-capital as of June 30, 2023.

Other income, net. Other income, net was $0.4 million for the three months ended June 30, 2024, a decrease of $0.2 million, or 28.6%, as compared to other income, net of $0.5 million for the three months ended June 30, 2023.

(37)

Six Months Ended June 30, 2024 compared to Six Months Ended June 30, 2023

| Six Months Ended June 30, |
(in thousands) | 2024 |  | 2023 |  | $ Change |  | % Change |
Revenue |  |  |  |  |  |  |  |
Medicare risk-based revenue | $ | 323,359 |  | $ | 277,079 |  | $ | 46,280 |  |  | 16.7 | %
Medicaid risk-based revenue |  | 60,518 |  |  | 55,680 |  |  | 4,838 |  |  | 8.7 | %
Government value-based care revenue |  | 33,505 |  |  | 32,216 |  |  | 1,288 |  |  | 4.0 | %
Other revenue |  | 13,491 |  |  | 32,449 |  |  | (18,958 | ) |  | (58.4 | %)
Total revenue |  | 430,872 |  |  | 397,424 |  |  | 33,449 |  |  | 8.4 | %
Operating expenses |  |  |  |  |  |  |  |
External provider costs |  | 334,056 |  |  | 267,668 |  |  | 66,388 |  |  | 24.8 | %
Cost of care |  | 85,726 |  |  | 78,819 |  |  | 6,907 |  |  | 8.8 | %
Sales and marketing |  | 4,441 |  |  | 7,092 |  |  | (2,651 | ) |  | (37.4 | %)
Corporate, general and administrative |  | 34,888 |  |  | 44,813 |  |  | (9,926 | ) |  | (22.1 | %)
Depreciation and amortization |  | 13,218 |  |  | 13,404 |  |  | (187 | ) |  | (1.4 | %)
Impairment of long-lived assets |  | 132,990 |  |  | — |  |  | 132,990 |  |  | 100.0 | %
Goodwill impairment |  | — |  |  | 98,000 |  |  | (98,000 | ) |  | (100.0 | %)
Total operating expenses |  | 605,318 |  |  | 509,797 |  |  | 95,521 |  |  | 18.7 | %
Operating loss |  | (174,446 | ) |  | (112,373 | ) |  | (62,073 | ) |  | (55.2 | %)
Nonoperating (expenses) income |  |  |  |  |  |  |  |
Interest expense |  | (40,131 | ) |  | (23,908 | ) |  | (16,224 | ) |  | (67.9 | %)
Change in fair value of derivative liabilities |  | (26 | ) |  | 1,540 |  |  | (1,567 | ) |  | (101.7 | %)
Gain on remeasurement of contingent earnout liabilities |  | — |  |  | 19,916 |  |  | (19,916 | ) |  | (100.0 | %)
Other income, net |  | 992 |  |  | 721 |  |  | 271 |  |  | 37.5 | %
Total nonoperating expenses |  | (39,165 | ) |  | (1,730 | ) |  | (37,435 | ) |  | (2,163.7 | %)
Loss before income taxes |  | (213,612 | ) |  | (114,103 | ) |  | (99,509 | ) |  | (87.2 | %)
Income tax expense |  | (354 | ) |  | (355 | ) |  | 1 |  |  | 0.2 | %
Net loss | $ | (213,966 | ) | $ | (114,458 | ) | $ | (99,507 | ) |  | (86.9 | %)

* Figures may not sum due to rounding

Medicare risk-based revenue. Medicare risk-based revenue was $323.4 million for the six months ended June 30, 2024, an increase of $46.3 million, or 16.7%, compared to $277.1 million for the six months ended June 30, 2023. This increase was driven primarily by a 17.4% increase in the total number of at-risk Medicare patients, and a favorable net prior period development of approximately $13.0 million. In addition, revenue recognized during the six months ended June 30, 2023, was impacted by the unfavorable net prior period development of $22.8 million mainly due to more current membership data received during that period.

Medicaid risk-based revenue. Medicaid risk-based revenue was $60.5 million for the six months ended June 30, 2024, an increase of $4.8 million, or 8.7%, compared to $55.7 million for the six months ended June 30, 2023. This increase was driven primarily by a 35.5% increase in rates, partially offset by 19.8% decrease in the total number of at-risk Medicaid patients.

Government value-based care revenue. Government value-based care revenue was $33.5 million for the six months ended June 30, 2024, an increase of $1.3 million, or 4.0%, compared to $32.2 million for the six months ended June 30, 2023.

Other revenue. Other revenue was $13.5 million for the six months ended June 30, 2024, a decrease of $19.0 million, or 58.4%, compared to $32.4 million for the six months ended June 30, 2023. The decrease is primarily due to a decrease in partial risk revenue, as risk contracts are converted to full risk, and the impact of lower revenue from incentive based programs.

External provider costs. External provider costs were $334.1 million for the six months ended June 30, 2024, an increase of $66.4 million, or 24.8%, compared to $267.7 million for the six months ended June 30, 2023. This increase was driven primarily by an increase in claim costs and a 9.2% increase in the total number of at-risk patients, partially offset by the favorable net prior period development of $12.0 million. In addition, external provider costs recognized during the six months ended June 30, 2023, were impacted by unfavorable net prior period development of $21.2 million mainly due to more current membership data received during that period.

Cost of care. Cost of care expenses were $85.7 million for the six months ended June 30, 2024, an increase of $6.9 million, or 8.8%, compared to $78.8 million for the six months ended June 30, 2023. The increase is due to increases in pharmacy costs, partially offset by a reduction in headcount and payroll related costs in the current period, as compared to the prior period.

(38)

Sales and marketing expenses. Sales and marketing expenses were $4.4 million for the six months ended June 30, 2024, a decrease of $2.7 million, or 37.4%, compared to $7.1 million for the six months ended June 30, 2023. The decrease is due to a reduction in our sales staff and marketing efforts in 2024 as compared to 2023, related to our effort to reduce operating expenses.

Corporate, general and administrative expenses. Corporate, general and administrative expenses were $34.9 million for the six months ended June 30, 2024, a decrease of $9.9 million, or 22.1%, compared to $44.8 million for the six months ended June 30, 2023. The decrease is primarily due to lower payroll-related expenses, related to our initiative to reduce operating expenses.

Depreciation and amortization expenses. Depreciation and amortization expenses were $13.2 million for the six months ended June 30, 2024, a decrease of $0.2 million, or 1.4%, compared to $13.4 million for the six months ended June 30, 2023.

Impairment of long-lived assets. Impairment of long-lived assets was $133.0 million for the six months ended June 30, 2024, which included impairment of intangible assets, ROU assets and property and equipment. Refer to Note 1, Description of Business and Going Concern, in our condensed consolidated financial statements included in this Report for further information.

Goodwill impairment. During the six months ended June 30, 2023, the Company recognized a goodwill impairment of $98.0 million. This impairment was mainly the result of the reduction of the market value of the Company's Class A Common Stock. Refer to Note 5, Goodwill And Other Intangibles Assets, in our condensed consolidated financial statements included in this Report for further information.

Interest expense. Interest expense were $40.1 million for the six months ended June 30, 2024, an increase of $16.2 million, or 67.9%, compared to $23.9 million for the six months ended June 30, 2023. This increase was due to the increased borrowings and higher weighted-average interest rate. Refer to Note 7, Debt and Related Party Debt, in our condensed consolidated financial statements included in this Report for additional information on the borrowings outstanding as of June 30, 2024.

Change in fair value of derivative liabilities. The Company recorded a loss on fair value of derivative liabilities less than $0.1 million for the six months ended June 30, 2024, a decrease of $1.6 million, or 101.7%, compared to a gain of $1.5 million for the six months ended June 30, 2023. This decrease was driven by the decrease in market value of the Company’s Class A Common Stock during the prior period.

Gain on remeasurement of contingent earnout liabilities. We recorded a gain of $19.9 million for the six months ended June 30, 2023. This gain was driven by the decrease in the market value of the Company’s Class A Common Stock since December 31, 2022. There was no activity during the six months ended June 30, 2024 due to the contingent earnout consideration being reclassified into additional paid-in-capital as of June 30, 2023.

Other income, net. Other income, net was $1.0 million for the six months ended June 30, 2024, an increase of $0.3 million, or 37.5%, as compared to $0.7 million for the six months ended June 30, 2023.

Liquidity and Capital Resources

Overview

As of June 30, 2024, we had cash and cash equivalents of $16.4 million.

Our principal sources of liquidity have been cash generated by our centers and MSO operations, and borrowings under our credit facilities. We have used these funds to meet our capital requirements, which consist of salaries and labor, benefits and other employee-related costs, product and supply costs, third-party customer service, billing and collections and logistics costs, capital expenditures including patient equipment, center and office lease expenses, insurance premiums, acquisitions, and debt service.

Our future capital expenditures will depend on many factors, including patient volume, revenue growth rates, the pace and scale of our expansion in new and existing markets and any future acquisitions. Many of our capital expenditures are made in advance of patients beginning service. Certain operating costs are incurred at the beginning of the equipment service period and during initial patient set up. We may be required to seek additional equity or debt financing, in addition to cash on hand and borrowings under our credit facilities in connection with operating or growing our business, including debt financing that

(39)

may be available to us from certain health plans for each new center that we open under the terms of our agreements with those health plans. In the event that additional financing is required from outside sources, we may not be able to raise it on acceptable terms or at all. If additional capital is unavailable when desired, our business, results of operations, and financial condition would be materially and adversely affected.

Refer to Note 1, Description of Business and Going Concern, to the condensed consolidated financial statements that appear elsewhere in this Report for details regarding our going concern considerations. As a result of our recent financial performance and current projections, we do not expect to be in compliance with the maximum leverage ratio and minimum liquidity covenants specified in the Credit Agreement or with financial covenants on certain lease agreements for the twelve months from the date of issuance of the condensed consolidated financial statements that appear elsewhere in this Report. As a result, the indebtedness outstanding under the Credit Agreement, and certain operating and finance lease liabilities related to agreements with which we were in default, were classified as current within the condensed consolidated balance sheets.

Credit Facilities

Credit Agreement

In May 2022, the Company entered into a credit agreement (the “Credit Agreement”) that provided for an aggregate of up to $300 million in term loans, comprised of (i) initial term loans in the aggregate principal amount of $190 million (the “Initial Term Loans”) and (ii) a delayed term loan facility in the aggregate principal amount of $110 million (the “Delayed Draw Term Loans”). The Credit Agreement permits the Company to enter into certain incremental facilities subject to compliance with the terms, conditions and covenants set forth therein. In May 2022, the Company drew $190.0 million of the Initial Term Loans and used approximately $121.0 million of the net proceeds from this borrowing to repay its outstanding obligations under Existing Credit Agreement and recognized related debt extinguishment losses of $6.2 million.

The Credit Agreement contains embedded derivatives related to optional and mandatory prepayments, default interest and the impact of potential legislative changes. Embedded derivatives are separated from the host contract, and are carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument. The Company has concluded that certain embedded derivatives within the Credit Agreement meet these criteria and, as such, are valued separate and apart from the Credit Agreement and are recorded at fair value each reporting period.

In March 2023, the Company entered into the Second Amendment to the Credit Agreement. The Second Amendment amended the Credit Agreement to, among other things, (i) provide for a new incremental delayed draw term loan B facility in an aggregate principal amount of $60.0 million; (ii) revise the commitment expiration date for the Company’s existing $110.0 million Delayed Draw Term Loan to forty-five days following the Amendment Closing Date, (iii) extend the commencement of amortization payments on loans under the Credit Agreement from March 31, 2024 to May 31, 2025; (iv) reduce the amount of interest that the Company may elect to capitalize from 4.00% to 3.50% beginning on the second anniversary of the execution date of the Credit Agreement, 3.00% beginning on the third anniversary of the execution date of the Credit Agreement, and 1.50% beginning on December 10, 2025; (v) increase the amount of the super-priority revolving credit facility that is permitted to be added to the Credit Agreement to $45.0 million and provide that the entirety of such facility may be used for general corporate purposes; and (vi) amend the prepayment provisions of the Credit Agreement, including to have such provisions run as of the Amendment Closing Date.

The Credit Agreement contains certain covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, liens or encumbrances, to make certain investments, to enter into sale-leaseback transactions or sell certain assets, to make certain restricted payments or pay dividends, to enter into consolidations, to transact with affiliates and to amend certain agreements, subject in each case to the exceptions and other qualifications as provided in the Credit Agreement. The Credit Agreement also contains covenants that require the Company to satisfy a minimum liquidity requirement of $50.0 million, which may be decreased to $25.0 million if the Company achieves a certain adjusted EBITDA, and maintain a maximum total net leverage ratio based on the Company’s consolidated EBITDA, as defined in the Credit Agreement, with de novo losses excluded from the calculation of such ratio for up to 36 months after the opening of a de novo center, which maximum total leverage ratio will initially be 8.50 to 1.00, commencing with the fiscal quarter ended September 30, 2022 and is subject to a series of step-downs. For the fiscal quarters ending September 30, 2026 and thereafter the Company must maintain a maximum total net leverage ratio no greater than 5.50 to 1.00.

(40)

On March 15, 2024 (the “Third Amendment Effective Date”), the Company entered into a Waiver and Third Amendment to Credit Agreement (the “Third Amendment”) among us, certain of our subsidiaries, as guarantors, the lenders party thereto and Jefferies Finance LLC, as administrative agent and collateral agent. The Third Amendment amended the Credit Agreement to, among other things, (i) waive certain events of default under the Credit Agreement in the limited manner set forth therein through May 15, 2024 (the “Third Amendment Specified Period”), subject to an earlier termination of the waiver upon the occurrence of certain specified events; (ii) increase the applicable margin rate by 2.00% during the Third Amendment Specified Period, which additional interest we may elect to capitalize as principal amount on the outstanding loans; and (iii) modify certain covenants contained in the Credit Agreement, including, but not limited to, reducing the minimum liquidity requirement to $10 million during the Third Amendment Specified Period and providing for additional reporting to the lenders.

On May 14, 2024, the Company entered into a Limited Waiver and Fourth Amendment to the Credit Agreement (the “Fourth Amendment”). The Fourth Amendment amended the Credit Agreement to, among other things, extend the waiver of certain events of default under the Credit Agreement in the limited manner set forth therein through June 17, 2024 (the “Temporary Waiver Period”), subject to an earlier termination of the waiver upon the occurrence of certain specified events.

On June 17, 2024, the Company entered into a Limited Waiver and Fifth Amendment to the Credit Agreement (the “Fifth Amendment”). The Fifth Amendment amended the Credit Agreement to extend the waiver of certain events of default under the Credit Agreement in the limited manner set forth therein through June 24, 2024, subject to an earlier termination of the waiver upon the occurrence of certain specified events.

On June 21, 2024, the Company entered into a Limited Waiver and Sixth Amendment to the Credit Agreement (the “Sixth Amendment”). The Sixth Amendment amended the Credit Agreement to extend the waiver of certain events of default under the Credit Agreement in the limited manner set forth therein through June 28, 2024, subject to an earlier termination of the waiver upon the occurrence of certain specified events.

On June 28, 2024, the Company entered into a Limited Waiver and Seventh Amendment to the Credit Agreement (the “Seventh Amendment”). The Seventh Amendment amended the Credit Agreement to extend the waiver of certain events of default under the Credit Agreement in the limited manner set forth therein through July 8, 2024, subject to an earlier termination of the waiver upon the occurrence of certain specified events.

As of June 30, 2024, there was no remaining availability under the Delayed Draw Term Loans.

Based on the elections made by the Company, as of June 30, 2024, borrowings under the Credit Agreement bore interest of Term SOFR (calculated as the Secured Overnight Financing Rate published on the Federal Reserve Bank of New York’s website, plus the applicable credit spread adjustment based on the elected interest period) plus an applicable margin rate of 11.00%. As permitted under the Credit Agreement, the Company elected to capitalize 6.00% of the interest as principal amount. As a result of this election, the cash interest component of the applicable margin increased by 0.50%. Amortization payments under the Credit Agreement are payable in quarterly installments, commencing on May 31, 2025, in aggregate principal amounts equal to 0.25% of the aggregate outstanding principal amount of Initial Term Loans and Delayed Draw Term Loans. All amounts owed under the Credit Agreement are due in May 2027.

As of June 30, 2024, the Company was in compliance with all of the financial covenants under the Credit Agreement, as amended through the Seventh Amendment.

Loan and Security Agreement

In November 2022, the Company entered into a Loan and Security Agreement (the “Loan and Security Agreement”), by and among Sparta Merger Sub I Inc., a Delaware corporation and wholly-owned subsidiary of the Company, Sparta Merger Sub II Inc., a Delaware corporation and wholly-owned subsidiary of the Company, Sparta Merger Sub I LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (“Merger LLC I”), Sparta Merger Sub II LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (together with Merger LLC I, the “Guarantors”), Steward Accountable Care Network, Inc. (n/k/a as Steward Accountable Care Network, LLC) and Steward National Care Network, Inc. (n/k/a Steward National Care Network, LLC), as borrowers (the “Borrowers”), CAJ Lending LLC (“CAJ”) and Deerfield Partners L.P., as lenders (the “Lenders”), and CAJ, as administrative agent and collateral agent (in such capacity, the “Agent”). Mr. Carlos A. de Solo, a director of the Company and the Company’s President and Chief Executive Officer, Mr. Alberto de Solo, the Company’s Executive Vice President and Chief Operating Officer, and Mr. Joseph N. De Vera, the Company’s Senior Vice President and Legal Counsel, have interests in CAJ.

(41)

Pursuant to the Loan and Security Agreement, the Lenders provided the Borrowers a term loan (the “Term Loan”) in the aggregate principal amount of $35.5 million. The Company used the proceeds of the Term Loan to fund the Financed Net Pre-Closing Medicare AR acquired in connection with the Steward Acquisition.

The Term Loan bore an interest rate at 12.0% per annum. In addition, the Borrowers paid a facility fee equal to 3.0% of the aggregate principal amount of the Term Loan.

The Loan and Security Agreement matured on the earlier of November 30, 2023, or three business days after the Borrowers receive payment for the Financed Net Pre-Closing Medicare AR from the federal government. In October 2023, the Company paid off all outstanding indebtedness of $35.5 million due under the Loan and Security Agreement with the proceeds of the MSSP payment from the federal government, and the Loan and Security Agreement was terminated.

Elevance Health Collaboration Agreement

In connection with our collaboration agreement with Elevance Health, Elevance Health has agreed to provide debt financing of up to $1.0 million for each new center opened in partnership with Elevance Health.

In October 2022, in connection with the Elevance Health Collaboration Agreement we entered into a promissory note for an amount of $1.0 million, due in October 2032. Funds received from Elevance Health pursuant to the aforementioned promissory note will be used to finance costs of one new center that was opened in partnership with Elevance Health.

Finance Leases

We lease certain of our center facilities under non-cancelable finance lease agreements. Refer to Note 12, Leases, in the notes to the condensed consolidated financial statements for additional information, including the schedule of remaining lease payments. The remaining duration of such leases ranges from 19 to 20 years.

The Company’s finance leases, two of the operating leases, and one lease that has not yet commenced, contain various covenants, that require the Company, among other things, to maintain minimum consolidated stockholder's equity of $100.0 million and a minimum cash balance of $25.0 million. Refer to Note 12, Leases, in the notes to the condensed consolidated financial statements for information regarding events of default on certain of our leases.

Cash Flows

The following table summarizes our cash flows for the periods presented:

| Six Months Ended June 30, |
(in thousands) | 2024 |  |  | 2023 |
Net cash used in operating activities | $ | (48,114 | ) |  | $ | (43,263 | )
Net cash used in investing activities |  | (794 | ) |  |  | (5,234 | )
Net cash (used in) provided by financing activities |  | (189 | ) |  |  | 61,477 |

Operating Activities. Net cash used in operating activities for the six months ended June 30, 2024 was $48.1 million, an increase of $4.9 million, as compared to $43.3 million used in operating activities during the six months ended June 30, 2023. This increase is primarily the result of the disbursement of a MSSP surety bond payment of $7.0 million during the six months ended June 30, 2024 (none in 2023).

Investing Activities. Net cash used in investing activities was $0.8 million and $5.2 million for the six months ended June 30, 2024 and 2023, respectively, driven by investments in leasehold improvements and medical equipment for our centers.

Financing Activities. Net cash used in financing activities was $0.2 million, during the six months ended June 30, 2024, which consisted of payments related to financed equipment purchases. Net cash provided by financing activities was $61.5 million during the six months ended June 30, 2023, driven mainly by the $62.0 million drawn on our Delayed Draw Term Facility, net of the related discount and issuance costs.

(42)

Contractual Obligations and Commitment s

Our principal commitments consist of obligations under the Credit Agreement and operating and finance leases for our centers.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of June 30, 2024, or 2023, other than operating or finance leases which have not yet commenced.

JOBS Act

Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies, but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, as an emerging growth company, we can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our consolidated financial statements with a public company which is neither an emerging growth company, nor an emerging growth company that has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.

Critical Accounting Policies and Estimates

Other than as noted below, there have been no material changes to our Critical Accounting Estimates presented in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 18, 2024.

Impairment of Long-Lived Assets

Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value.

Fair value estimates used in the impairment review of long-lived assets are determined using a future cash flow model involving several assumptions. Changes in the Company’s assumptions could materially impact fair value estimates. Assumptions critical to our fair value estimates are: (i) projected cash flows and (ii) discount rates. These and other assumptions may change in the future based on specific facts and circumstances. While the Company believes the assumptions used to estimate the future cash flows are reasonable, there can be no assurance that the expected future cash flows will be realized. As a result, impairment charges that possibly would have been recognized in earlier periods may not be recognized until later periods if actual results deviate unfavorably from estimates. The use of different assumptions would increase or decrease discounted cash flows, therefore, could change impairment determinations.

Asset impairment charges are recognized based on the relative fair value of the long-lived assets. Asset impairment charges are recognized in impairments of long-lived assets in our condensed consolidated statements of operations.

The Company identified triggering events as of June 30, 2024 and evaluated its long-lived assets for impairments. Fair value of the Company's assets groups was determined based on a discounted cash flow method. Based on the assessment performed, the Company recognized long-lived asset impairment charges of $133.0 million.

Interim Goodwill Assessment

The Company’s policy is to test goodwill for impairment annually on December 31, or on an interim basis if an event triggering impairment may have occurred. The Company identified triggering events as of June 30, 2024 and tested goodwill for

(43)

impairment. Fair value of the Company’s single reporting unit was based on the Company’s market capitalization. Based on this analysis, no goodwill impairment was identified.

The Company estimates that a decrease of 1% in the value of the Company’s Class A common stock would not result in recognition of goodwill impairment.

Recent Accounting Pronouncements

Refer to Note 2, Summary of Significant Accounting Policies, to our condensed consolidated financial statements included in this Report, for additional information.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

(44)

Item 4. Contro ls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Under supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2024. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of June 30, 2024, due to the material weaknesses in internal control over financial reporting described below.

Notwithstanding the identified material weaknesses described further below, our management has performed additional analyses, reconciliations, and other post-closing procedures and has concluded that the condensed consolidated financial statements included in this Form 10-Q fairly represent in all material respects the financial condition, results of operations and cash flows of the Company for the periods presented.

Material Weaknesses in Internal Control over Financial Reporting

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

As previously disclosed in Management’s Report on Internal Control over Financial Reporting in Item 9A of the Form 10-K for the fiscal year ended December 31, 2023, the following material weaknesses were identified as of December 31, 2023: We lack a sufficient complement of professionals with the appropriate level of knowledge, training and experience to appropriately analyze, record and disclose accounting matters commensurate with our accounting and reporting requirements as a public company. This material weakness contributed to the Company not designing and maintaining formal controls to analyze, account for and disclose complex transactions, including the accounting for financial instruments and contingent earnout liabilities. These material weaknesses resulted in:

•
the restatement of the Company’s previously filed consolidated financial statements as of and for the year ended December 31, 2020, as well as the quarterly condensed consolidated financial information for the 2020 interim period ended September 30, 2020 related to derivative warrant liabilities, Class A ordinary shares subject to possible redemption, additional paid-in-capital, retained earnings/(deficit), fair value adjustment on derivative warrant liabilities, earnings per share and the related disclosures;
•
the restatement of the Company’s previously filed quarterly condensed consolidated financial information for the 2021 interim periods ended June 30, 2021 and September 30, 2021 related to goodwill, contingent earnout liabilities, additional paid-in capital, retained earnings/(deficit), gain/(loss) on remeasurement of earnout liabilities, earnings per share and the related disclosures; and
•
the restatement of the Company’s previously filed consolidated financial statements as of and for the year ended December 31, 2021, as well as the quarterly condensed consolidated financial information for the 2021 interim period ended September 30, 2021 and the 2022 interim periods ended March 31, 2022, June 30, 2022, and September 30, 2022 related to other current assets and other assets.

Subsequent to the evaluation performed as of December 31, 2023, management identified an additional material weakness as t he Company did not design and maintain effective controls over the accounting for revenue and accounts receivable transactions, including controls to validate the terms of the underlying revenue and accounts receivable transactions were appropriately recorded. This material weakness, which was determined to have existed as of December 31, 2023, resulted in immaterial misstatements in revenue, external provider costs, accounts receivable, net, and risk settlement liabilities as of and for the years ended December 31, 2023 and December 31, 2022, and the quarterly condensed consolidated financial statements for the periods ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30, 2023, September 30, 2023 and March 31, 2024.

(45)

These material weaknesses could result in misstatements of substantially all accounts or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.

Remediation Plan for the Material Weaknesses

Since identifying the material weaknesses previously disclosed in Item 9A of the Form 10-K for the fiscal year ended December 31, 2023, management has developed a remediation plan and implemented measures to address the underlying causes of each material weakness. Our efforts to date included the following:

•
We engaged an external advisor to assist in evaluating and documenting the design and operating effectiveness of our internal control over financial reporting.
•
In 2022, we hired a Vice President of Financial Reporting and Technical Accounting and a Chief Accounting Officer, both with technical public company accounting and financial reporting experience.
•
We enhanced access to accounting training, literature, research materials and documents for our finance and accounting departments.
•
During the second and third quarters of 2023, we performed a financial statement risk assessment and identified areas where new key controls are needed, or existing controls needed to be enhanced.
•
During the second and third quarters of 2023, we designed and implemented controls to address the entity level and financial reporting risks identified, including those involving accounting for complex transactions, including financial instruments and contingent earnout liabilities.
•
During the second and third quarters of 2023, together with our external advisor, we designed a formal testing program to evaluate the design and operating effectiveness of key controls and began executing the formal testing program.
•
During the third and fourth quarters of 2023, our external advisor performed key control testing consistent with our formal testing program.

With respect to the additional material weakness related to the accounting for revenue and accounts receivable transactions, we are still developing our remediation plan, which will include (i) evaluating the staffing level, skills and qualification of personnel responsible for accounting for these transactions, (ii) enhancement of the design of our existing control activities and processes for revenue recognition and (iii) improving the detailed review process of our revenue recognition models.

Although we have implemented controls as of June 30, 2024 related to the previously identified material weaknesses, the controls have not been in place and operating effectively for a sufficient period to evaluate if the material weaknesses have been remediated. Although no assurance can be made that such remediation will occur, or that additional material weaknesses will not be identified, we believe we are making progress toward achieving the effectiveness of our internal control over financial reporting and disclosure controls and procedures. The actions that we are taking are subject to ongoing senior management review, as well as Audit Committee oversight. We may also conclude that additional measures may be required to remediate the material weaknesses in our internal control over financial reporting, which may necessitate additional changes to the design and implementation of controls.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2024, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

(46)

PA RT II. – OTHER INFORMATION

I tem 1. Legal Proceedings

From time to time, CareMax may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business. Although the results of litigation and claims are inherently unpredictable and uncertain, CareMax is not currently a party to any legal proceedings the outcome of which, if determined adversely to CareMax, are believed to, either individually or taken together, have a material adverse effect on CareMax’s business, operating results, cash flows or financial condition, except as set forth in “Litigation” of Note 14, Commitments and Contingencies, to our condensed consolidated financial statements included in this Report. Regardless of the outcome, litigation has the potential to have an adverse impact on CareMax because of defense and settlement costs, diversion of management resources, and other factors.

Item 1A. Risk Factors

Except as set forth below, there have been no material changes to the principal risks that we believe to be material to our business, results of operations and financial condition, from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023.

Our rights under existing agreements could be impaired as a result of bankruptcy proceedings brought by Steward Health Care System.

In connection with the closing of the Steward Acquisition, CareMax and Steward Health Care Network, Inc. (“SHCN”) entered into an exclusive access agreement pursuant to which SHCN is required to exclusively make its participating provider network available to CareMax for the provision of services to MA members under MA risk agreements for an initial period of ten years, with a ten-year automatic renewal term, unless either party provides 180 days’ notice prior to the expiration of the initial term of its decision not to renew. In connection with the access agreement and other ancillary agreements, SHCN delegated its rights, duties and obligations with respect to MA risk contracting to CareMax, including, without limitation, SHCN’s right to enforce certain exclusivity provisions in its agreements with participating providers. For a period of two years following the date of the Steward Acquisition, SHCN is contractually obligated to remove any participating provider from its network who terminates its provider agreement contract with CareMax. Further, CareMax entered into exclusive direct participating provider agreements with Steward Health Care System’s captive physician practices for an initial term of ten years with a ten-year automatic renewal term unless either party provides 180 days’ notice prior to the expiration of the initial term of its decision not to renew.

On May 6, 2024, Steward Health Care System and certain of its affiliates commenced an in-court restructuring process through the filing of voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas. In June 2024, as part of these bankruptcy proceedings, Steward Health Care System moved to reject certain of the executory contracts between Steward Health Care System and/or its affiliates and CareMax and/or its affiliates, including, but not limited to, the exclusive access agreement and employed provider participating provider agreements and other ancillary agreements.

If the Bankruptcy Court grants Steward Health Care Network’s motion to reject the executory contracts, it could have a material adverse effect on our business, financial condition and results of operations, in particular with respect to the MSO.

I tem 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

It em 3. Defaults Upon Senior Securities

None.

It em 4. Mine Safety Disclosures

None.

Ite m 5. Other Information

Securities trading plans of Directors and Executive Officers

(47)

During the last fiscal quarter, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) informed us of the adoption and termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K.

Ite m 6. Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this Report.

No. |  | Description of Exhibit
10.1+* |  | Limited Waiver and Fourth Amendment to Credit Agreement, dated May 14, 2024 by and among CareMax, Inc., the subsidiary guarantors party thereto, the lenders party thereto and Jefferies Finance LLC, as administrative agent and collateral agent.
10.2+* |  | Limited Waiver and Fifth Amendment to Credit Agreement, dated June 17, 2024 by and among CareMax, Inc., the subsidiary guarantors party thereto, the lenders party thereto and Jefferies Finance LLC, as administrative agent and collateral agent.
10.3+* |  | Limited Waiver and Sixth Amendment to Credit Agreement, dated June 21, 2024 by and among CareMax, Inc., the subsidiary guarantors party thereto, the lenders party thereto and Jefferies Finance LLC, as administrative agent and collateral agent.
10.4+* |  | Limited Waiver and Seventh Amendment to Credit Agreement, dated June 28, 2024 by and among CareMax, Inc., the subsidiary guarantors party thereto, the lenders party thereto and Jefferies Finance LLC, as administrative agent and collateral agent.
31.1* |  | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2* |  | Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1** |  | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2** |  | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS* |  | Inline XBRL Instance Document
101.CAL* |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH* |  | Inline XBRL Taxonomy Extension Schema Document
101.DEF* |  | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* |  | Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE* |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104* |  | Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

** Furnished herewith.

+ Certain portions of this exhibit have been omitted pursuant to Regulation S-K, Item (601)(b)(10).
† Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

(48)

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| CareMax Inc.
Date: August 9, 2024 |  | /s/ Carlos A. de Solo
| Name: | Carlos A. de Solo
| Title: | President, Chief Executive Officer, and Director (Principal Executive Officer)
Date: August 9, 2024 |  | /s/ Kevin Wirges
| Name: | Kevin Wirges
| Title: | Executive Vice President, Chief Financial Officer and Treasurer (Principal Financial and Principal Accounting Officer)

(49)